

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 15 16 17 18 19 20

chain bonds :

1-10 5-14 6-13 14-15

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 15-16 15-20  
16-17 17-18 18-19 19-20

exact/norm bonds :

1-2 1-6 1-10 2-3 3-4 4-5 5-6 5-14 6-13 14-15

normalized bonds :

7-8 7-12 8-9 9-10 10-11 11-12 15-16 15-20 16-17 17-18 18-19 19-20

isolated ring systems :

containing 1 : 7 : 15 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom  
20:Atom

L1 STRUCTURE UPLOADED

=&gt; d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=&gt; s l1

SAMPLE SEARCH INITIATED 14:58:36 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 25 TO ITERATE

100.0% PROCESSED 25 ITERATIONS

19 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 200 TO 800

PROJECTED ANSWERS: 119 TO 641

Habte

07/30/2007

L2 19 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 14:58:45 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 518 TO ITERATE

100.0% PROCESSED 518 ITERATIONS  
SEARCH TIME: 00.00.01

311 ANSWERS

L3 311 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 14:58:48 ON 30 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Jul 2007 VOL 147 ISS 6

FILE LAST UPDATED: 29 Jul 2007 (20070729/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 23 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2007:64328 CAPLUS  
 DOCUMENT NUMBER: 147:66742  
 TITLE: Novel imaging agents for fibrosis  
 INVENTOR(S): Tolleshaug, Helge; Newton, Ben; Rydbeck, Anna;  
 Chettibi, Salah; Eriksen, Morten  
 PATENT ASSIGNEE(S): GE Healthcare Limited, UK  
 SOURCE: PCT Int. Appl., 56pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007066119	A2	20070614	WO 2006-GB4579	20061207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GM, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:		GB 2005-24991		A 20051208

AB The present invention provides a novel imaging agent suitable for the non-invasive visualization of fibrosis. A method for the preparation of the imaging agent is also provided by the invention, as well as a precursor for use in said method. Also provided is a pharmaceutical composition comprising the imaging agent and a kit for the preparation of the pharmaceutical. In a further aspect, use of the imaging agent for in vivo imaging and in the preparation of a medicament for the diagnosis of a condition in which LOX is upregulated is provided.

IT 941314-91-6P CAPLUS  
 RL: DGN (Diagnostic use); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (novel imaging agents for fibrosis)  
 RN 941314-91-6 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 941314-92-7 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




IT 941314-86-9P 941314-87-0P 941591-43-1P  
 941591-44-2P  
 RL: DGN (Diagnostic use); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (novel imaging agents for fibrosis)  
 RN 941314-86-9 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 941314-87-0 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED




RN 941591-43-1 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




RN 941591-44-2 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




IT 620617-01-8P 941314-90-5P  
RL: DGN (Diagnostic use); RCT (Reactant); SPN (Synthetic preparation);  
BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);  
USES (Uses)  
(novel imaging agents for fibrosis)  
RN 620617-01-8 CAPLUS  
CN 3(2H)-Pyridazinone, 5-(4-ethyl-1-piperazinyl)-4-[(4'-hydroxy(1,1'-  
biphenyl)-4-yl)oxy]-2-(4-methylphenyl)- (CA INDEX NAME)

L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 941314-90-5 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[1,6-dihydro-5-[(4'-iodo(1,1'-biphenyl)-4-  
yl)oxy]-1-(4-methylphenyl)-6-oxo-4-pyridazinyl]-, 1,1-dimethylethyl ester  
(CA INDEX NAME)



L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 2006:493002 CAPLUS  
DOCUMENT NUMBER: 145:8178  
TITLE: Preparation of 2-phenyl-3-pyridazinones as lysoyl  
oxidase inhibitors  
PATENT ASSIGNEE(S): Burchardt, Elmar Reinhold, Germany  
SOURCE: Ger. Offen., 28 pp.  
CODEN: GWXXBX  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 102004056226	A1	20060524	DE 2004-102004056226	20041122
WO 2006053555	A2	20060526	WO 2005-DE2086	20051120
WO 2006053555	A3	20060727		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,  
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC,  
VN, VU, ZA, ZH, ZW  
RW: AT, BE, BO, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
CF, CO, CI, CM, GA, GN, GD, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM


PRIORITY APPLN. INFO.: DE 2004-102004056226A 20041122

OTHER SOURCE(S): MARPAT 145:8178  
GI




AB Title compds. 1 (R1 = alkyl, arylmethyl, etc.; R2 = H, halo, amino, etc.;  
Ar1, Ar2 = 5 to 7-membered aryl group with proviso; X = O, S, NH, etc.).  
In lysoyl oxidase inhibition assays, phenylpyridazinone II exhibited an  
IC50 value of 1100 nM.  
IT 620617-76-7 887762-08-5 887762-09-6


L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 887762-10-9  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (prepn. of phenylpyridazinones as lyeal oxidase inhibitors)  
 RN 620617-76-7 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-([1,1'-biphenyl]-4-yloxy)-2-(4-chlorophenyl)-5-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



RN 887762-08-5 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-5-(1H-imidazol-1-yl)-4-[4-(2-methoxyethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 887762-09-6 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[4-(3-hydroxypropyl)phenoxy]-5-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 887762-10-9 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-5-(1H-imidazol-1-yl)-4-[4-propylphenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2005:78233 CAPLUS  
 DOCUMENT NUMBER: 142:176853  
 TITLE: Preparation of substituted pyridazinones as inhibitors of p38 kinase  
 INVENTOR(S): Hepperle, Michael; Jerome, Kevin; Walker, John; Selness, Shaun; Devraj, Rajesh  
 PATENT ASSIGNEE(S): Pharmacia Corporation, USA  
 SOURCE: U.S. Pat. Appl. Publ., 65 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005020594	A1	20050127	US 2004-893073	20040716
PRIORITY APPLN. INFO.:			US 2003-488378P	P 20030718


OTHER SOURCE(S): CASREACT 142:176853; MARPAT 142:176853  
 GI




AB Title compds. I [wherein R1 = H, halo, NO2, (un)substituted alkyl, alkoxy or alkanoyl; R2 = H, OH, halo, (un)substituted alkyl, alkoxy, alkynyl or amino; R3 = H, halo, (un)substituted alkoxy, carbonyl or alkyl; R5 = H, (un)substituted (hetero)aryl or alkyl; etc.] and pharmaceutically acceptable salts thereof were prepared as p38 kinase inhibitors. For example, cyclocondensation of mucobromic acid with 2,6-dichlorophenylhydrazine-HCl followed by etherification of the resultant dibromopyridazinone with 4-fluorobenzyl alc. gave II. The analogs of II, 4-bromo-2-(2,6-dichlorophenyl)pyridazin-3(2H)-ones, showed inhibition of human p38 alpha kinase with IC50 values of 0.1-20 μM. Thus, I and their pharmaceutically compns. are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity, such as inflammation and cancer.

IT 565157-32-6P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of substituted pyridazinones as inhibitors of p38 kinase)  
 RN 565157-32-6 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(2,6-dichlorophenyl)-4-phenoxy-5-(2-phenylethoxy)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)





L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L4 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2007 ACS ON STN  
 ACCESSION NUMBER: 2005:74103 CAPLUS  
 DOCUMENT NUMBER: 142:176852  
 TITLE: Preparation of substituted pyridazinones as

inhibitors  
 of p38  
 INVENTOR(S): Devraj, Rajesh; Happerle, Michael; Jerome, Kevin;  
 Salness, Shaun; Walker, John Keith  
 PATENT ASSIGNEE(S): Pharmacia Corporation, USA  
 SOURCE: PCT Int. Appl., 169 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005007632	A1	20050127	WO 2004-1B2229	20040705
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SN, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VC, VN, YU, ZA, ZM, ZW				
RW: BM, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, GU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:		US 2003-468378P P 20030718		
OTHER SOURCE(S): CASREACT 142:176852; MARPAT 142:176852				
GI				



AB Title compds. represented by the formula I [wherein R1 = H, halo, NO2, (aryl)alkyl, (halo)alkoxy, etc.; R2 = H, OH, halo, (aryl)alkoxy, (dialkyl)amino, etc.; R3 = H, halo, alkoxycarbonyl, (aryl)alkyl, etc.; R4 = H, (hetero)aryl, (un)substituted (arylthio)alkyl, etc.] and pharmaceutically acceptable salts thereof were prepared as p38 inhibitors.

For example, reaction of mucobromic acid with 2,6-dichlorophenylhydrazine-HCl, followed by reaction with 4-fluorobenzyl

own work

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS ON STN  
 ACCESSION NUMBER: 2003:872263 CAPLUS  
 DOCUMENT NUMBER: 139:364943  
 TITLE: Preparation of 2-phenyl-3(2H)-pyridazinones as lysyl  
 oxidase inhibitors for preventing and treating  
 fibrosis  
 INVENTOR(S): Schohe-Loop, Rudolf; Burchardt, Elmar; Faeste,  
 Christiane; Hirth-Dietrich, Claudia; Kaldenich,  
 Joerg;  
 Knorr, Andreas; Lampe, Thomas; Naab, Paul; Schmidt,  
 Delf; Schmidt, Gunther  
 PATENT ASSIGNEE(S): Bayer AG, Germany  
 SOURCE: Ger. Offen., 106 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10216144	A1	20031106	DE 2002-10216144	20020412
CA 2482151	A1	20031127	CA 2003-2482151	20030408
WO 2003097612	A1	20031127	WO 2003-EP3628	20030408
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003224049	A1	20031202	AU 2003-224049	20030408
EP 1497269	A1	20050119	EP 2003-720434	20030408
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 200608898	T	20060316	JP 2004-505345	20030408
US 2006004015	A1	20060105	US 2005-511225	20050711
PRIORITY APPLN. INFO.:		DE 2002-10216144 A 20020412		
		WO 2003-EP3628 W 20030408		


OTHER SOURCE(S): MARPAT 139:364943  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [wherein R1 = (un)substituted 5- to 7-membered heterocyclic ring selected from imidazolyl, triazolyl, pyridinyl, piperazinyl, 1,4-diazacycloheptyl, morpholinyl, thiomorpholinyl, etc.; R2 = (un)substituted (hetero)aryl; R3 = H, halo, alkyl, CF3, NO2, CN, CO2H or alkoxycarbonyl; and their salts, solvates, and solvates of their salts] were prepared as lysyl oxidase inhibitors for preventing and treating fibrosis in humans and/or animals. For example, II was prepared by

Habte

L4 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
 alc. gave II. The derivs. of II,  
 4-bromo-2-(2,6-dichlorophenyl)pyridazin-  
 3(2H)-ones, showed inhibition of human p38 alpha kinase with IC50 values  
 of 0.1-20 μM. Thus, I and their pharmaceutically compns. are useful  
 for treating diseases and conditions caused or exacerbated by unregulated  
 p38 MAP Kinase and/or TNF activity.  
 IT 565157-32-6P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (Preparation of substituted pyridazinones as inhibitors of p38)  
 RN 565157-32-6 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(2,6-dichlorophenyl)-4-phenoxy-5-(2-phenylethoxy)-  
 (9CI) (CA INDEX NAME)




REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR  
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
 alkylation of tert-Bu 1-piperazinecarboxylate with  
 2-(4-chlorophenyl)-4,5-  
 dichloro-3(2H)-pyridazinone in dioxane in the presence of NaI at  
 100°, reaction of the 5-chloropyridazinone intermediate with  
 potassium 4-phenylphenoxide in DMF, followed by Boc-deprotection.  
 Selected I exhibited excellent IC50 values in the range of 0.003 μM to  
 0.017 μM for the inhibition of lysyl oxidase compared to BAPN (10  
 μM) and structurally related amorphones (5-4 μM). Selected I was  
 tested for its antifibrotic activity in rats and was found active in  
 the chronic CCl4 poisoning model, the bile duct ligation model, and the  
 serum-induced liver fibrosis model.  
 IT 620619-15-OP, 4,5-Bis[(1,1'-biphenyl-4-yl)oxy]-2-(4-chlorophenyl)-  
 3(2H)-pyridazinone 620619-16-1P, 4-[(1,1'-Biphenyl-4-yl)oxy]-5-  
 chloro-2-(4-chlorophenyl)-3(2H)-pyridazinone 620619-17-2P,  
 4-(4-Bromophenoxy)-5-chloro-2-(4-chlorophenyl)-3(2H)-pyridazinone  
 620619-18-3P, 5-Bromo-2-(4-chlorophenyl)-4-[(4'-fluoro-4-  
 biphenyl)oxy]-3(2H)-pyridazinone 620619-19-4P,  
 5-Chloro-2-(4-chlorophenyl)-4-[(2'-methoxymethoxy-4'-fluoro-4-  
 biphenyl)oxy]-3(2H)-pyridazinone 620619-20-7P,  
 5-Chloro-2-(4-chlorophenyl)-4-[(2',4'-difluoro-4-biphenyl)oxy]-3(2H)-  
 pyridazinone 620619-21-8P, 5-Azido-4-[(1,1'-biphenyl-4-yl)oxy]-2-  
 (4-chlorophenyl)-3(2H)-pyridazinone 620619-22-9P,  
 5-Azido-4-(4-bromophenoxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone  
 620619-23-OP, 5-Azido-2-(4-chlorophenyl)-4-[(4'-fluoro-4-  
 biphenyl)oxy]-3(2H)-pyridazinone 620619-24-1P,  
 5-Azido-2-(4-chlorophenyl)-4-[(2'-methoxymethoxy-4'-fluoro-4-biphenyl)oxy]-  
 3(2H)-pyridazinone 620619-25-2P, 5-Azido-2-(4-chlorophenyl)-4-  
 [(2',4'-difluoro-4-biphenyl)oxy]-3(2H)-pyridazinone 620619-26-5P,  
 4-(4-Bromophenoxy)-2-(4-chlorophenyl)-5-(4-(2-hydroxyethyl)-1-  
 piperazinyl)-3(2H)-pyridazinone 620619-30-9P,  
 2-(4-Chlorophenyl)-5-(1H-imidazol-1-yl)-4-(4,4,5,5-tetramethyl-1,3,2-  
 dioxaborolan-2-yl)phenoxy)-3(2H)-pyridazinone 620619-31-OP,  
 2-(4-Chlorophenyl)-5-(4-(2-hydroxyethyl)-1-piperazinyl)-4-(4,4,5,5-  
 tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-3(2H)-pyridazinone  
 620619-35-4P, 4-(4-Bromophenoxy)-2-(4-chlorophenyl)-5-(1H-imidazol-  
 1-yl)-3(2H)-pyridazinone 620619-50-3P, 4-(4-Bromophenoxy)-2-(4-  
 methylphenyl)-5-(1H-imidazol-1-yl)-3(2H)-pyridazinone 620619-51-4P,  
 4-(4-Bromophenoxy)-2-(4-(ethoxycarbonyl)phenyl)-5-(1H-imidazol-1-yl)-  
 3(2H)-pyridazinone 620619-52-5P, 4-(4-Bromophenoxy)-2-[3-  
 (trifluoromethyl)phenyl]-5-(1H-imidazol-1-yl)-3(2H)-pyridazinone  
 620619-53-6P, 4-(4-Bromophenoxy)-2-[4-(tert-butyl)phenyl]-5-(1H-  
 imidazol-1-yl)-3(2H)-pyridazinone 620619-54-7P,  
 4-(4-Bromophenoxy)-2-(4-fluorophenyl)-5-(1H-imidazol-1-yl)-3(2H)-  
 pyridazinone 620619-55-8P, 4-(4-Bromophenoxy)-2-[3-fluorophenyl]-  
 5-(1H-imidazol-1-yl)-3(2H)-pyridazinone 620619-56-9P, tert-Butyl


4-[5-(4-bromophenoxy)-1-(4-chlorophenyl)-6-oxo-1,6-dihydropyridazin-4-yl]-  
 1-piperazine carboxylate 620619-57-OP, 4-(4-Bromophenoxy)-2-(4-  
 chlorophenyl)-5-(3-oxo-1-piperazinyl)-3(2H)-pyridazinone  
 620619-58-1P, 4-(4-Bromophenoxy)-2-(4-chlorophenyl)-5-(4-acetyl-1-  
 piperazinyl)-3(2H)-pyridazinone 620619-59-3P,  
 4-(4-Bromophenoxy)-2-(4-chlorophenyl)-5-(4-methylsulfonyl-1-piperazinyl)-  
 3(2H)-pyridazinone 620619-60-5P, 4-(4-Bromophenoxy)-2-(4-  
 chlorophenyl)-5-(4-(cyclopropylcarbonyl)-1-piperazinyl)-3(2H)-pyridazinone  
 620619-61-6P, 4-(4-Bromophenoxy)-2-(4-methylphenyl)-5-(4-acetyl-1-  
 piperazinyl)-3(2H)-pyridazinone 620619-62-7P,  
 4,5-Di-(4-Bromophenoxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone

07/30/2007

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 620619-63-8P, 4-(4-Bromophenoxy)-2-(4-chlorophenyl)-5-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3(2H)-pyridazinone 620619-64-9P, 4-(4-Bromophenoxy)-2-(4-chlorophenyl)-5-(4-hydroxy-1-piperidinyl)-3(2H)-pyridazinone 620619-65-0P, 4-(4-Bromophenoxy)-2-(4-chlorophenyl)-5-(4-aminocarbonyl-1-piperazinyl)-3(2H)-pyridazinone 620619-66-1P, 4-(4-Bromophenoxy)-2-(4-chlorophenyl)-5-(4-(tert-butylidimethylsilyloxy)methyl)-1,2,3-triazol-1-yl)-3(2H)-pyridazinone 620619-67-3P, 4-(4-Bromophenoxy)-2-(4-chlorophenyl)-5-(4-(2-hydroxymethyl)-1,2,3-triazol-1-yl)-3(2H)-pyridazinone  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; prepn. of phenylpyridazinones as lysyl oxidase inhibitors for treatment of fibrosis)  
 RN 620619-15-0 CAPLUS  
 CN 3(2H)-Pyridazinone, 4,5-bis([1,1'-biphenyl]-4-yloxy)-2-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 620619-16-1 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-([1,1'-biphenyl]-4-yloxy)-5-chloro-2-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 620619-17-2 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-(4-bromophenoxy)-5-chloro-2-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 CN 3(2H)-Pyridazinone, 5-azido-4-([1,1'-biphenyl]-4-yloxy)-2-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 620619-22-9 CAPLUS  
 CN 3(2H)-Pyridazinone, 5-azido-4-(4-bromophenoxy)-2-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 620619-23-0 CAPLUS  
 CN 3(2H)-Pyridazinone, 5-azido-2-(4-chlorophenyl)-4-[(4'-fluoro[1,1'-biphenyl]-4-yloxy)- (9CI) (CA INDEX NAME)




RN 620619-24-1 CAPLUS  
 CN 3(2H)-Pyridazinone, 5-azido-2-(4-chlorophenyl)-4-[(4'-fluoro-2'-(methoxymethoxy)[1,1'-biphenyl]-4-yloxy)- (9CI) (CA INDEX NAME)




RN 620619-25-2 CAPLUS  
 CN 3(2H)-Pyridazinone, 5-azido-2-(4-chlorophenyl)-4-[(2',4'-difluoro[1,1'-

Habte


L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620619-18-3 CAPLUS  
 CN 3(2H)-Pyridazinone, 5-bromo-2-(4-chlorophenyl)-4-[(4'-fluoro[1,1'-biphenyl]-4-yloxy)- (9CI) (CA INDEX NAME)



RN 620619-19-4 CAPLUS  
 CN 3(2H)-Pyridazinone, 5-chloro-2-(4-chlorophenyl)-4-[(4'-fluoro-2'-(methoxymethoxy)[1,1'-biphenyl]-4-yloxy)- (9CI) (CA INDEX NAME)




RN 620619-20-7 CAPLUS  
 CN 3(2H)-Pyridazinone, 5-chloro-2-(4-chlorophenyl)-4-[(2',4'-difluoro[1,1'-biphenyl]-4-yloxy)- (9CI) (CA INDEX NAME)




RN 620619-21-8 CAPLUS


L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 biphenyl]-4-yloxy)- (9CI) (CA INDEX NAME)



RN 620619-28-5 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-(4-bromophenoxy)-2-(4-chlorophenyl)-5-[4-(2-hydroxyethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 620619-30-9 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-5-[1H-imidazol-1-yl]-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 620619-31-0 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-5-[4-(2-hydroxyethyl)-1-piperazinyl]-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]- (9CI) (CA INDEX NAME)

07/30/2007


L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 620619-35-4 CAPLUS  
CN 3(2H)-Pyridazinone,  
4-(4-bromophenoxy)-2-(4-chlorophenyl)-5-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 620619-50-3 CAPLUS  
CN 3(2H)-Pyridazinone, 4-(4-bromophenoxy)-5-(1H-imidazol-1-yl)-2-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 620619-51-4 CAPLUS  
CN Benzoic acid, 4-[5-(4-bromophenoxy)-4-(1H-imidazol-1-yl)-6-oxo-1(6H)-pyridazinyl]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
CN 3(2H)-Pyridazinone,  
4-(4-bromophenoxy)-2-[3-(4-bromophenyl)-5-(1H-imidazol-1-yl)]- (9CI) (CA INDEX NAME)



RN 620619-56-9 CAPLUS  
CN 1-Piperazinecarboxylic acid,  
4-[5-(4-bromophenoxy)-1-(4-chlorophenyl)-1,6-dihydro-6-oxo-4-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 620619-57-0 CAPLUS  
CN 3(2H)-Pyridazinone, 4-(4-bromophenoxy)-2-(4-chlorophenyl)-5-(3-oxo-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 620619-58-1 CAPLUS  
CN Piperazine,  
1-acetyl-4-[5-(4-bromophenoxy)-1-(4-chlorophenyl)-1,6-dihydro-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620619-52-5 CAPLUS  
CN 3(2H)-Pyridazinone, 4-(4-bromophenoxy)-5-(1H-imidazol-1-yl)-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 620619-53-6 CAPLUS  
CN 3(2H)-Pyridazinone, 4-(4-bromophenoxy)-2-(4-(1,1-dimethylethyl)phenyl)-5-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 620619-54-7 CAPLUS  
CN 3(2H)-Pyridazinone,  
4-(4-bromophenoxy)-2-(4-fluorophenyl)-5-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 620619-55-8 CAPLUS


L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 620619-59-2 CAPLUS  
CN Piperazine, 1-[5-(4-bromophenoxy)-1-(4-chlorophenyl)-1,6-dihydro-6-oxo-4-pyridazinyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 620619-60-5 CAPLUS  
CN Piperazine, 1-[5-(4-bromophenoxy)-1-(4-chlorophenyl)-1,6-dihydro-6-oxo-4-pyridazinyl]-4-(cyclopropylcarbonyl)- (9CI) (CA INDEX NAME)




RN 620619-61-6 CAPLUS  
CN Piperazine,  
1-acetyl-4-[5-(4-bromophenoxy)-1-(4-chlorophenyl)-1,6-dihydro-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620619-62-7 CAPLUS  
CN 3(2H)-Pyridazinone, 4,5-bis(4-bromophenoxy)-2-(4-chlorophenyl)- (9CI)  
(CA INDEX NAME)



RN 620619-63-8 CAPLUS  
CN 3(2H)-Pyridazinone, 4-(4-bromophenoxy)-2-(4-chlorophenyl)-5-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)- (9CI) (CA INDEX NAME)



RN 620619-64-9 CAPLUS  
CN 3(2H)-Pyridazinone, 4-(4-bromophenoxy)-2-(4-chlorophenyl)-5-(4-hydroxy-1-piperidinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
(hydroxymethyl)-1H-1,2,3-triazol-1-yl]- (9CI) (CA INDEX NAME)


IT 620616-97-9P, tert-Butyl 4-[5-[[4'-[(2,2-dimethylpropanoyl)oxy]-4-biphenyl]oxy]-1-(4-methylphenyl)-6-oxo-1,6-dihydropyridazin-4-yl]-1-piperazine carboxylate 620616-99-1P, 4'-[[2-(4-Methylphenyl)-3-oxo-5-(1-piperazinyl)-2,3-dihydro-4-pyridazinyl]oxy]-4-biphenyl pivalate Trifluoroacetate 620617-00-7P, 4'-[[5-(4-Ethyl-1-piperazinyl)-2-(4-methylphenyl)-3-oxo-5-(1-piperazinyl)-4-biphenyl]oxy]-4-biphenyl pivalate 620617-01-8P, 5-(4-Ethyl-1-piperazinyl)-4-[(4'-hydroxy-4-biphenyl)oxy]-2-(4-methylphenyl)-3(2H)-pyridazinone 620617-07-4P, tert-Butyl 4-[5-(4-biphenyloxy)-1-(4-chlorophenyl)-6-oxo-1,6-dihydro-4-pyridazinyl]-1-piperazine carboxylate 620617-08-5P, 4-(4-Biphenyloxy)-2-(4-chlorophenyl)-5-(1-piperazinyl)-3(2H)-pyridazinone 620617-09-6P, 4-(4-Biphenyloxy)-2-(4-chlorophenyl)-5-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3(2H)-pyridazinone 620617-10-9P, 4-(4-Biphenyloxy)-2-(4-chlorophenyl)-5-(4-oxopiperidin-1-yl)-3(2H)-pyridazinone 620617-11-0P, 4-(4-Biphenyloxy)-2-(4-chlorophenyl)-5-(4-hydroxypiperidin-1-yl)-3(2H)-pyridazinone 620617-15-4P, tert-Butyl [2-[4-[5-(4-Biphenyloxy)-1-(4-chlorophenyl)-6-oxo-1,6-dihydropyridazin-4-yl]piperazin-1-yl]-1-(S)-methyl-2-oxoethyl]carbamate 620617-19-8P 620617-22-3P, 4-(4-Biphenyloxy)-2-(4-chlorophenyl)-5-(1-oxido-4-thiomorpholinyl)-3(2H)-pyridazinone 620617-26-9P, 5-(1-Piperazinyl)-4-(4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone monohydrochloride 620617-42-7P, 5-(4-tert-Butoxycarbonylpiperazin-1-yl)-4-[(4'-hydroxy-4-biphenyl)oxy]-2-(4-chlorophenyl)-3(2H)-pyridazinone 620618-50-0P,

5-(1H-imidazol-1-yl)-4-[(2-amino-4-biphenyl)oxy]-2-(4-chlorophenyl)-3(2H)-pyridazinone


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(lysyl oxidase inhibitor; preparation of phenylpyridazinones as lysyl oxidase inhibitors for treatment of fibrosis)

RN 620616-97-9 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[5-[[4'-[(2,2-dimethyl-1-oxopropoxy)[1,1'-biphenyl]-4-yl]oxy]-1,6-dihydro-1-(4-methylphenyl)-6-oxo-4-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 620619-65-0 CAPLUS  
CN 1-Piperazinecarboxamide, 4-[5-(4-bromophenoxy)-1-(4-chlorophenyl)-1,6-dihydro-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 620619-66-1 CAPLUS  
CN 3(2H)-Pyridazinone, 4-(4-bromophenoxy)-2-(4-chlorophenyl)-5-[4-[[[1,1-dimethylethyl]dimethylsilyl]oxy]methyl]-1H-1,2,3-triazol-1-yl]- (9CI)  
(CA INDEX NAME)



RN 620622-81-3 CAPLUS  
CN 3(2H)-Pyridazinone, 4-(4-bromophenoxy)-2-(4-chlorophenyl)-5-(4-


L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 620616-99-1 CAPLUS  
CN Propanoic acid, 2,2-dimethyl-, 4'-[[2,3-dihydro-2-(4-methylphenyl)-3-oxo-5-(1-piperazinyl)-4-pyridazinyl]oxy][1,1'-biphenyl]-4-yl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 620616-98-0  
CMP C32 H34 N4 O4



CM 2


CRN 76-05-1

07/30/2007

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
CMP C2 H F3 O2




RN 620617-00-7 CAPLUS  
CN Propanoic acid, 2,2-dimethyl-,  
4'-[[5-(4-ethyl-1-piperazinyl)-2,3-dihydro-  
2-(4-methylphenyl)-3-oxo-4-pyridazinyl]oxy][1,1'-biphenyl]-4-yl ester  
(9CI) (CA INDEX NAME)




RN 620617-01-8 CAPLUS  
CN 3(2H)-Pyridazinone, 5-(4-ethyl-1-piperazinyl)-4-[[4'-hydroxy[1,1'-  
biphenyl]-4-yl]oxy]-2-(4-methylphenyl)- (CA INDEX NAME)


L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
RN 620617-09-6 CAPLUS  
CN 3(2H)-Pyridazinone,  
4-[[[1,1'-biphenyl]-4-yl]oxy]-2-(4-chlorophenyl)-5-(1,4-  
dioxo-8-azaaspiro[4.5]dec-8-yl)- (9CI) (CA INDEX NAME)



RN 620617-10-9 CAPLUS  
CN 3(2H)-Pyridazinone, 4-[[[1,1'-biphenyl]-4-yl]oxy]-2-(4-chlorophenyl)-5-(4-  
oxo-1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 620617-11-0 CAPLUS  
CN 3(2H)-Pyridazinone, 4-[[[1,1'-biphenyl]-4-yl]oxy]-2-(4-chlorophenyl)-5-(4-  
hydroxy-1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 620617-15-4 CAPLUS  
CN Carbamic acid,  
[[[1S]-2-[4-[[5-[[1,1'-biphenyl]-4-yl]oxy]-1-(4-chlorophenyl)-  
1,6-dihydro-6-oxo-4-pyridazinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Habte


L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620617-07-4 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[[5-[[[1,1'-biphenyl]-4-yl]oxy]-1-(4-  
chlorophenyl)-1,6-dihydro-6-oxo-4-pyridazinyl]-, 1,1-dimethylethyl ester  
(9CI) (CA INDEX NAME)




RN 620617-08-5 CAPLUS  
CN 3(2H)-Pyridazinone, 4-[[[1,1'-biphenyl]-4-yl]oxy]-2-(4-chlorophenyl)-5-(1-  
piperazinyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
Absolute stereochemistry.



RN 620617-19-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-5-[[3,6-dihydro-1(2H)-pyridinyl]-4-  
[[4'-fluoro[1,1'-biphenyl]-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 620617-22-3 CAPLUS  
CN 3(2H)-Pyridazinone, 4-[[[1,1'-biphenyl]-4-yl]oxy]-2-(4-chlorophenyl)-5-(1-  
oxido-4-thiomorpholinyl)- (9CI) (CA INDEX NAME)



07/30/2007


L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

RN 620617-36-9 CAPLUS  
CN 3(2H)-Pyridazinone, 4-[(1,1'-biphenyl)-4-yloxy]-2-(4-chlorophenyl)-5-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 620617-42-7 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[(1-(4-chlorophenyl)-1,6-dihydro-5-[(4'-hydroxy[1,1'-biphenyl]-4-yloxy]-6-oxo-4-pyridazinyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 620618-50-0 CAPLUS  
CN 3(2H)-Pyridazinone, 4-[(2'-amino[1,1'-biphenyl]-4-yloxy)-2-(4-chlorophenyl)-5-(1H-imidazol-1-yl)]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)


4-(4-Biphenyloxy)-2-(4-chlorophenyl)-5-(4-thiomorpholinyl)-3(2H)-pyridazinone 620617-29-0P, 5-(4-Morpholinyl)-4-[(4'-methylsulfonylamino-4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-30-3P, 4-(4-Biphenyloxy)-2-(4-chlorophenyl)-5-(4-methyl-1,4-diazacyclohexane)-3(2H)-pyridazinone monohydrochloride 620617-31-4P, 5-(4-Morpholinyl)-4-[(4'-hydroxy-4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-32-5P, 5-(4-Methylpiperazin-1-yl)-4-[(4'-hydroxy-4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-33-6P, 4-[(4'-Hydroxy-4-biphenyloxy)-2-(4-chlorophenyl)-5-(4-methyl-1,4-diazacyclohexane)-3(2H)-pyridazinone monohydrochloride 620617-34-7P, 5-(4-Methyl-1,4-diazacycloheptyl)-4-[(4'-hydroxy-4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-35-8P, 5-(4-Ethylpiperazin-1-yl)-4-(4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-36-9P, 5-(4-Ethylpiperazin-1-yl)-4-(4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-37-0P, 5-(4-Methyl-1,4-diazacycloheptyl)-4-[(4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-38-1P, 5-[(2-Hydroxyethyl)-1-piperazinyl]-4-(4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-39-2P,

5-[4-(2-Hydroxyethyl)-1-piperazinyl]-4-(4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone monohydrochloride 620617-40-5P, 5-(4-Methyl-1,4-diazacycloheptyl)-4-(4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone monohydrochloride 620617-41-6P, 5-(4-Ethylpiperazin-1-yl)-4-(4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone monohydrochloride 620617-43-8P,

5-(1-Piperazinyl)-4-[(4'-hydroxy-4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-44-9P, 5-(4-Acetyl-1-piperazinyl)-4-(4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-45-0P, 5-(4-Ethyl-1-piperazinyl)-4-[(4'-hydroxy-4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-46-1P, 5-(4-Ethyl-1-piperazinyl)-4-[(4'-hydroxy-4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone monohydrochloride 620617-47-2P, 5-(4-Ethoxycarbonyl-1-piperidinyl)-4-[(4'-hydroxy-4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-48-3P, 5-(4-Methylsulfonyl-1-piperazinyl)-4-(4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-49-4P, 5-(4-Ethoxycarbonyl-1-piperazinyl)-4-[(4'-hydroxy-4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-50-7P, 5-(4-(2-Methoxyethyl)-1-piperazinyl)-4-(4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-51-8P, 5-[(R)-2-Methyl-1-piperazinyl]-4-(4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-52-9P,

5-[(R)-2-Methyl-1-piperazinyl]-4-(4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone monohydrochloride 620617-53-0P, 5-(1-Piperazinyl)-4-(4-biphenyloxy)-2-(4-nitrophenyl)-3(2H)-pyridazinone 620617-54-1P, 5-(4-Methyl-1-piperazinyl)-4-(4-biphenyloxy)-2-(4-trifluoromethylphenyl)-3(2H)-pyridazinone monohydrochloride 620617-55-2P, 5-(4-Isopropyl-1-piperazinyl)-4-[(4'-hydroxy-4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-56-3P, 5-(4-Aminocarbonyl-1-piperazinyl)-4-(4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-57-4P, 5-(4-(Cyclopropylcarbonyl)-1-piperazinyl)-4-(4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-58-5P, 5-(4-Ethylsulfonyl-1-piperazinyl)-4-(4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-59-6P, 5-(4-(2-Propenyl)-1-piperazinyl)-4-(4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-60-9P, 5-(1-Piperazinyl)-4-(4-biphenyloxy)-2-(4-trifluoromethylphenyl)-3(2H)-pyridazinone

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



IT 620616-96-8P, N-[(4'-[(2-(4-Chlorophenyl)-5-(1H-imidazol-1-yl)-3-oxo-2,3-dihydropyridazin-4-yl)oxy]-4-biphenyl)-2-yl]-N-(methylsulfonyl)methanesulfonamide 620617-02-9P, 4-[(4'-Hydroxy-4-biphenyloxy)-2-(4-methylphenyl)-5-(4-methyl-1-piperazinyl)-3(2H)-pyridazinone 620617-03-0P, 5-(4-Ethyl-1-piperazinyl)-4-[(4'-hydroxy-4-biphenyloxy)-2-(4-methylphenyl)-3(2H)-pyridazinone Hydrochloride 620617-04-1P, 4-[(3'-Aminomethyl)-4'-fluoro-4-biphenyloxy]-2-(4-chlorophenyl)-5-[(4-methylsulfonyl)-1-piperazinyl]-3(2H)-pyridazinone 620617-05-2P, 2-(4-Chlorophenyl)-4-[(4'-fluoro-3'-(hydroxymethyl)-4-biphenyloxy)-5-(4-methylsulfonyl)-1-piperazinyl]-3(2H)-pyridazinone 620617-06-3P, 2-(4-Chlorophenyl)-5-(1H-imidazol-1-yl)-4-(4-pyridinyl)phenoxy-3(2H)-pyridazinone 620617-12-1P, 4-(4-Biphenyloxy)-2-(4-chlorophenyl)-5-(4-fluoro-piperidin-1-yl)-3(2H)-pyridazinone 620617-13-2P,

4-(4-Biphenyloxy)-2-(4-chlorophenyl)-5-(4,4-difluoro-piperidin-1-yl)-3(2H)-pyridazinone 620617-14-3P, 2-(4-Chlorophenyl)-4-[(4'-fluoro-4-biphenyloxy)-5-(4-chloropiperidin-1-yl)-3(2H)-pyridazinone 620617-16-5P, 4-(4-Biphenyloxy)-2-(chlorophenyl)-5-(4-L-alanyl-piperazin-1-yl)-3(2H)-pyridazinone 620617-17-6P, 4-[5-[(4'-Fluoro-4-biphenyloxy)-6-oxo-1-(4-trifluoromethylphenyl)-1,6-dihydropyridazin-4-yl]piperazine-1-carboxaldehyde 620617-18-7P,

4-(4-Biphenyloxy)-2-(4-chlorophenyl)-5-(4-cyclopropylpiperazin-1-yl)-3(2H)-pyridazinone 620617-20-1P, 2-(4-Chlorophenyl)-5-(3,4-dihydroxy-1-piperidinyl)-4-[(4'-fluoro-4-biphenyloxy)-3(2H)-pyridazinone 620617-21-2P, 2-(4-Chlorophenyl)-4-[(4'-fluoro-4-biphenyloxy)-5-(4-(hydroxymethyl)-1-piperidinyl)-3(2H)-pyridazinone 620617-23-4P, 4-(4-Biphenyloxy)-2-(4-chlorophenyl)-5-(1,1-dioxido-4-thiomorpholinyl)-3(2H)-pyridazinone 620617-24-5P, 4-(4-Biphenyloxy)-2-(4-chlorophenyl)-5-(4-methyl-1-piperazinyl)-3(2H)-pyridazinone 620617-25-6P, 4-(4-Biphenyloxy)-2-(4-chlorophenyl)-5-(4-morpholinyl)-3(2H)-pyridazinone 620617-26-7P, 4-(4-Biphenyloxy)-2-(4-methylphenyl)-5-(4-thiomorpholinyl)-3(2H)-pyridazinone 620617-27-8P, 4-(4-Biphenyloxy)-2-(4-methylphenyl)-5-(4-morpholinyl)-3(2H)-pyridazinone 620617-28-9P,

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

620617-61-0P, 5-(4-Isopropyl-1-piperazinyl)-4-[(4'-hydroxy-4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-62-1P

5-(4-(2-Pyrrolidinoethyl)-1-piperazinyl)-4-[(4'-hydroxy-4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-63-2P, 5-(4-Ethoxycarbonylmethyl-1-piperazinyl)-4-(4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-64-3P, 5-[4-(2-Dimethylaminoethyl)-1-piperazinyl]-4-(4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-65-4P,

5-(4-Isopropylsulfonyl-1-piperazinyl)-4-(4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-66-5P, 5-(4-Methylaminocarbonyl-1-piperazinyl)-4-(4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-67-6P, 5-(1H-Imidazol-1-yl)-4-[(4'-fluoro-4-biphenyloxy)-2-(4-nitrophenyl)-3(2H)-pyridazinone 620617-68-7P, 5-(1H-Imidazol-1-yl)-4-(4-biphenyloxy)-2-(4-ethoxycarbonylphenyl)-3(2H)-pyridazinone 620617-69-8P, 5-(1H-Imidazol-1-yl)-4-(4-biphenyloxy)-2-(3-fluorophenyl)-3(2H)-pyridazinone 620617-70-1P, 5-(1H-Imidazol-1-yl)-4-(4-biphenyloxy)-2-(4-fluorophenyl)-3(2H)-pyridazinone 620617-71-2P, 5-(1H-Imidazol-1-yl)-4-[(4'-cyano-4-biphenyloxy)-2-(4-methylphenyl)-3(2H)-pyridazinone 620617-72-3P, 5-(1H-Imidazol-1-yl)-4-(4-biphenyloxy)-2-(4-methylphenyl)-3(2H)-pyridazinone 620617-74-5P, 5-(1H-Imidazol-1-yl)-4-[(4'-cyano-4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-75-6P, 5-(1H-Imidazol-1-yl)-4-[(4'-hydroxy-4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-76-7P, 5-(1H-Imidazol-1-yl)-4-(4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-77-8P, 5-(1H-Imidazol-1-yl)-4-[(4'-methylsulfonylamino-4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-78-9P, 5-(4-Acetyl-1-piperazinyl)-4-(4-biphenyloxy)-2-(4-methylphenyl)-3(2H)-pyridazinone 620617-79-0P, 5-(4-Acetyl-1-piperazinyl)-4-[(4'-fluoro-4-biphenyloxy)-2-(4-methylphenyl)-3(2H)-pyridazinone 620617-80-3P, 5-(1H-Imidazol-1-yl)-4-[(3'-carbonylamino-4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-81-4P,

5-(4-Carbonyl-1-piperazinyl)-4-(4-biphenyloxy)-2-(4-methylphenyl)-3(2H)-pyridazinone 620617-82-5P, 5-(4-Carbonyl-1-piperazinyl)-4-[(4'-fluoro-4-biphenyloxy)-2-(4-methylphenyl)-3(2H)-pyridazinone 620617-83-6P, 5-(1H-Imidazol-1-yl)-4-[(3'-methylsulfonylamino-4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-84-7P,

5-(4-Methylsulfonyl-1-piperazinyl)-4-(4-biphenyloxy)-2-(4-methylphenyl)-3(2H)-pyridazinone 620617-85-8P, 5-(4-Methylsulfonyl-1-piperazinyl)-4-[(4'-fluoro-4-biphenyloxy)-2-(4-methylphenyl)-3(2H)-pyridazinone 620617-86-9P, 5-(4-Methylsulfonyl-1-piperazinyl)-4-[(2'-methoxymethoxy-4'-fluoro-4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-87-0P, 5-(4-Methylsulfonyl-1-piperazinyl)-4-[(3'-methylsulfonylamino-4'-fluoro-4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-88-1P, 5-(4-Methylsulfonyl-1-piperazinyl)-4-[(2'-methylsulfonylamino-4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-89-2P,

5-(4-Methylsulfonyl-1-piperazinyl)-4-[(2',4'-difluoro-4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-90-5P, 5-(4-Methylsulfonyl-1-piperazinyl)-4-[(2'-methoxy-4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone 620617-91-6P,

5-(4-Methylsulfonyl-1-piperazinyl)-4-[(2'-[methylsulfonylamino]methyl)-4'-fluoro-4-biphenyloxy)-2-(4-chlorophenyl)-3(2H)-pyridazinone

Habte

07/30/2007



L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
biphenyl)oxy]-2-(4-chlorophenyl)-3(2H)-pyridazinone 620619-00-3P

5-(4-Acetyl-1-piperazinyl)-4-[(3'-methylsulfonylamino-4-biphenyl)oxy]-2-(4-chlorophenyl)-3(2H)-pyridazinone 620619-01-4P,

5-(4-Acetyl-1-piperazinyl)-4-[(2'-[(acetylamino)methyl]-4-biphenyl)oxy]-2-(4-chlorophenyl)-3(2H)-pyridazinone 620619-02-5P,

5-(4-Acetyl-1-piperazinyl)-4-[(3'-[(acetylamino)methyl]-4'-fluoro-4-biphenyl)oxy]-2-(4-chlorophenyl)-3(2H)-pyridazinone 620619-03-6P

5-(4-Acetyl-1-piperazinyl)-4-[(3'-[(acetylamino)methyl]-4-biphenyl)oxy]-2-(4-chlorophenyl)-3(2H)-pyridazinone 620619-04-7P,

5-(4-Acetyl-1-piperazinyl)-4-[(3'-amino-4'-fluoro-4-biphenyl)oxy]-2-(4-chlorophenyl)-3(2H)-pyridazinone 620619-05-8P,

5-(4-Acetyl-1-piperazinyl)-4-[(3'-aminomethyl-4-biphenyl)oxy]-2-(4-chlorophenyl)-3(2H)-pyridazinone 620619-06-9P,

5-(4-Acetyl-1-piperazinyl)-4-[(3'-aminomethyl-4'-fluoro-4-biphenyl)oxy]-2-(4-chlorophenyl)-3(2H)-pyridazinone


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(lysyl oxidase inhibitor; prepn. of phenylpyridazinones as lysyl oxidase inhibitors for treatment of fibrosis)

RN 620616-96-8 CAPLUS

CN Methanesulfonamide,


N-[4'-[(2-(4-chlorophenyl)-2,3-dihydro-5-(1H-imidazol-1-yl)-3-oxo-4-pyridazinyl)oxy][1,1'-biphenyl]-2-yl]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 620617-02-9 CAPLUS


CN 3(2H)-Pyridazinone, 4-[(4'-hydroxy[1,1'-biphenyl]-4-yl)oxy]-2-(4-methylphenyl)-5-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 620617-05-2 CAPLUS


CN Piperazine, 1-[1-(4-chlorophenyl)-5-[(4'-fluoro-3'-(hydroxymethyl)[1,1'-biphenyl]-4-yl)oxy]-1,6-dihydro-6-oxo-4-pyridazinyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 620617-06-3 CAPLUS


CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-5-(1H-imidazol-1-yl)-4-[4-(pyridinyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 620617-03-0 CAPLUS


CN 3(2H)-Pyridazinone, 5-(4-ethyl-1-piperazinyl)-4-[(4'-hydroxy[1,1'-biphenyl]-4-yl)oxy]-2-(4-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



RN 620617-04-1 CAPLUS


CN Piperazine, 1-[5-[(3'-amino-4'-fluoro[1,1'-biphenyl]-4-yl)oxy]-1-(4-chlorophenyl)-1,6-dihydro-6-oxo-4-pyridazinyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620617-12-1 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(1,1'-biphenyl)-4-yloxy]-2-(4-chlorophenyl)-5-(4-fluoro-1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 620617-13-2 CAPLUS


CN 3(2H)-Pyridazinone, 4-[(1,1'-biphenyl)-4-yloxy]-2-(4-chlorophenyl)-5-(4,4-difluoro-1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 620617-14-3 CAPLUS


CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-5-(4-chloro-1-piperidinyl)-4-[(4'-fluoro[1,1'-biphenyl]-4-yl)oxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620617-16-5 CAPLUS  
 CN Piperazine,  
 1-[(2S)-2-amino-1-oxopropyl]-4-{5-[(1,1'-biphenyl)-4-yloxy]-1-(4-chlorophenyl)-1,6-dihydro-6-oxo-4-pyridazinyl}- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 620617-17-6 CAPLUS  
 CN 1-Piperazinecarboxaldehyde,  
 4-{5-[(4'-fluoro[1,1'-biphenyl]-4-yl)oxy]-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyridazinyl}- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620617-21-2 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-{4-(4-chlorophenyl)-4-[(4'-fluoro[1,1'-biphenyl]-4-yl)oxy]-5-[4-(hydroxymethyl)-1-piperidinyl]}- (9CI) (CA INDEX NAME)




RN 620617-23-4 CAPLUS  
 CN 3(2H)-Pyridazinone,  
 4-{[(1,1'-biphenyl)-4-yloxy]-2-(4-chlorophenyl)-5-(1,1-dioxido-4-thiomorpholinyl)}- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620617-18-7 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-{[(1,1'-biphenyl)-4-yloxy]-2-(4-chlorophenyl)-5-(4-cyclopropyl-1-piperazinyl)}- (9CI) (CA INDEX NAME)




RN 620617-20-1 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-{4-(4-chlorophenyl)-5-{3,4-dihydroxy-1-piperidinyl}-4-[(4'-fluoro[1,1'-biphenyl]-4-yl)oxy]}- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 620617-24-5 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-{[(1,1'-biphenyl)-4-yloxy]-2-(4-chlorophenyl)-5-(4-methyl-1-piperazinyl)}- (9CI) (CA INDEX NAME)




RN 620617-25-6 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-{[(1,1'-biphenyl)-4-yloxy]-2-(4-chlorophenyl)-5-(4-morpholinyl)}- (9CI) (CA INDEX NAME)




RN 620617-26-7 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-{[(1,1'-biphenyl)-4-yloxy]-2-(4-methylphenyl)-5-(4-thiomorpholinyl)}- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 620617-27-8 CAPLUS  
CN 3(2H)-Pyridazinone, 4-([1,1'-biphenyl]-4-yloxy)-2-(4-methylphenyl)-5-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 620617-28-9 CAPLUS  
CN 3(2H)-Pyridazinone, 4-([1,1'-biphenyl]-4-yloxy)-2-(4-chlorophenyl)-5-(4-thiomorpholinyl)- (9CI) (CA INDEX NAME)




RN 620617-29-0 CAPLUS  
CN Methanesulfonamide, N-[4'-[2-(4-chlorophenyl)-2,3-dihydro-5-(4-morpholinyl)-3-oxo-4-pyridazinyl]oxy]-[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620617-32-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[(4'-hydroxy[1,1'-biphenyl]-4-yl)oxy]-5-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 620617-33-6 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[(4'-hydroxy[1,1'-biphenyl]-4-yl)oxy]-5-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620617-30-3 CAPLUS  
CN 3(2H)-Pyridazinone, 4-([1,1'-biphenyl]-4-yloxy)-2-(4-chlorophenyl)-5-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 620617-31-4 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[(4'-hydroxy[1,1'-biphenyl]-4-yl)oxy]-5-(4-morpholinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● HCl

RN 620617-34-7 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-5-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-4-[(4'-hydroxy[1,1'-biphenyl]-4-yl)oxy]- (9CI) (CA INDEX NAME)




RN 620617-35-8 CAPLUS  
CN 3(2H)-Pyridazinone, 4-([1,1'-biphenyl]-4-yloxy)-2-(4-chlorophenyl)-5-(4-ethyl-1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 620617-37-0 CAPLUS  
CN 3(2H)-Pyridazinone, 4-([1,1'-biphenyl]-4-yloxy)-2-(4-chlorophenyl)-5-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)- (9CI) (CA INDEX NAME)




RN 620617-38-1 CAPLUS  
CN 3(2H)-Pyridazinone, 4-([1,1'-biphenyl]-4-yloxy)-2-(4-chlorophenyl)-5-[4-(2-hydroxyethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 620617-39-2 CAPLUS  
CN 3(2H)-Pyridazinone, 4-([1,1'-biphenyl]-4-yloxy)-2-(4-chlorophenyl)-5-[4-(2-hydroxyethyl)-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● HCl

RN 620617-43-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[(4'-hydroxy[1,1'-biphenyl]-4-yloxy)-5-(1-piperazinyl)]- (9CI) (CA INDEX NAME)




RN 620617-44-9 CAPLUS  
CN Piperazine, 1-acetyl-4-[5-([1,1'-biphenyl]-4-yloxy)-1-(4-chlorophenyl)-1,6-dihydro-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 620617-45-0 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-5-(4-ethyl-1-piperazinyl)-4-[(4'-hydroxy[1,1'-biphenyl]-4-yloxy)]- (9CI) (CA INDEX NAME)


Habte

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl


RN 620617-40-5 CAPLUS  
CN 3(2H)-Pyridazinone, 4-([1,1'-biphenyl]-4-yloxy)-2-(4-chlorophenyl)-5-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 620617-41-6 CAPLUS  
CN 3(2H)-Pyridazinone, 4-([1,1'-biphenyl]-4-yloxy)-2-(4-chlorophenyl)-5-(4-ethyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 620617-46-1 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-5-(4-ethyl-1-piperazinyl)-4-[(4'-hydroxy[1,1'-biphenyl]-4-yloxy)]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 620617-47-2 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[1-(4-chlorophenyl)-1,6-dihydro-5-[(4'-hydroxy[1,1'-biphenyl]-4-yloxy)-6-oxo-4-pyridazinyl]-, ethyl ester (9CI) (CA INDEX NAME)


07/30/2007



L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620617-48-3 CAPLUS  
 CN Piperazine,  
 1-[(1,1'-biphenyl)-4-yloxy]-1-(4-chlorophenyl)-1,6-dihydro-  
 6-oxo-4-pyridazinyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 620617-49-4 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[(1-(4-chlorophenyl)-1,6-dihydro-5-[(4'-  
 hydroxy[1,1'-biphenyl]-4-yloxy)-6-oxo-4-pyridazinyl]-, ethyl ester (9CI)  
 (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 620617-52-9 CAPLUS  
 CN 3(2H)-Pyridazinone,  
 4-[(1,1'-biphenyl)-4-yloxy]-2-(4-chlorophenyl)-5-[(2R)-  
 2-methyl-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HCl

RN 620617-53-0 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-[(1,1'-biphenyl)-4-yloxy]-2-(4-nitrophenyl)-5-(1-  
 piperazinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620617-50-7 CAPLUS  
 CN 3(2H)-Pyridazinone,  
 4-[(1,1'-biphenyl)-4-yloxy]-2-(4-chlorophenyl)-5-(4-(2-  
 methoxyethyl)-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 620617-51-8 CAPLUS  
 CN 3(2H)-Pyridazinone,  
 4-[(1,1'-biphenyl)-4-yloxy]-2-(4-chlorophenyl)-5-[(2R)-  
 2-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620617-54-1 CAPLUS  
 CN 3(2H)-Pyridazinone,  
 4-[(1,1'-biphenyl)-4-yloxy]-5-(4-methyl-1-piperazinyl)-  
 2-(4-(trifluoromethyl)phenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 620617-55-2 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-[(4'-hydroxy[1,1'-biphenyl]-4-yloxy)-5-(4 (1-  
 methylethyl)-1-piperazinyl)-2-(4-(trifluoromethyl)phenyl)- (9CI) (CA  
 INDEX NAME)



L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 RN 620617-56-3 CAPLUS  
 CN 1-Piperazinecarboxamide,  
 4-[5-([1,1'-biphenyl]-4-yloxy)-1-(4-chlorophenyl)-  
 1,6-dihydro-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 620617-57-4 CAPLUS  
 CN Piperazine,  
 1-[5-([1,1'-biphenyl]-4-yloxy)-1-(4-chlorophenyl)-1,6-dihydro-  
 6-oxo-4-pyridazinyl]-4-(cyclopropylcarbonyl)- (9CI) (CA INDEX NAME)




RN 620617-58-5 CAPLUS  
 CN 1-Piperazinecarboxamide,  
 4-[5-([1,1'-biphenyl]-4-yloxy)-1-(4-chlorophenyl)-  
 1,6-dihydro-6-oxo-4-pyridazinyl]-N-ethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620617-62-1 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[(4'-hydroxy[1,1'-biphenyl]-4-yloxy)-5-(4-[2-(1-pyrrolidinyl)ethyl]-1-piperazinyl)- (9CI) (CA INDEX NAME)




PAGE 1-A


L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 620617-59-6 CAPLUS  
 CN 3(2H)-Pyridazinone,  
 4-([1,1'-biphenyl]-4-yloxy)-2-(4-chlorophenyl)-5-(4-[2-  
 propenyl]-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 620617-60-9 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-([1,1'-biphenyl]-4-yloxy)-5-(1-piperazinyl)-2-(4-  
 (trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 620617-61-0 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[(4'-hydroxy[1,1'-biphenyl]-4-yloxy)-5-(4-(1-methylethyl)-1-piperazinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 2-A




RN 620617-63-2 CAPLUS  
 CN 1-Piperazineacetic acid,  
 4-[5-([1,1'-biphenyl]-4-yloxy)-1-(4-chlorophenyl)-  
 1,6-dihydro-6-oxo-4-pyridazinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 620617-64-3 CAPLUS  
 CN 3(2H)-Pyridazinone,  
 4-([1,1'-biphenyl]-4-yloxy)-2-(4-chlorophenyl)-5-(4-[2-  
 (dimethylamino)ethyl]-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 620617-65-4 CAPLUS  
 CN Piperazine,  
 1-[5-([1,1'-biphenyl]-4-yloxy)-1-(4-chlorophenyl)-1,6-dihydro-  
 6-oxo-4-pyridazinyl]-4-[(1-methylethylsulfonyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 620617-66-5 CAPLUS  
 CN 1-Piperazinecarboxamide,  
 4-[5-([1,1'-biphenyl]-4-yloxy)-1-(4-chlorophenyl)-  
 1,6-dihydro-6-oxo-4-pyridazinyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 620617-67-6 CAPLUS  
 CN 3(2H)-Pyridazinone,  
 4-[(4'-fluoro[1,1'-biphenyl]-4-yloxy)-5-(1H-imidazol-  
 1-yl)-2-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 620617-68-7 CAPLUS  
 CN Benzoic acid, 4-[5-([1,1'-biphenyl]-4-yloxy)-4-(1H-imidazol-1-yl)-6-oxo-  
 1(6H)-pyridazinyl]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 620617-69-8 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-([1,1'-biphenyl]-4-yloxy)-2-(3-fluorophenyl)-5-(1H-  
 imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 620617-70-1 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-([1,1'-biphenyl]-4-yloxy)-2-(4-fluorophenyl)-5-(1H-  
 imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 620617-71-2 CAPLUS  
 CN [1,1'-Biphenyl]-4-carbonitrile,  
 4'-[[2,3-dihydro-5-(1H-imidazol-1-yl)-2-(4-  
 methylphenyl)-3-oxo-4-pyridazinyl]oxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 620617-72-3 CAPLUS  
 CN 3(2H)-Pyridazinone,  
 4-([1,1'-biphenyl]-4-yloxy)-5-(1H-imidazol-1-yl)-2-(4-  
 methylphenyl)- (9CI) (CA INDEX NAME)




RN 620617-74-5 CAPLUS  
 CN [1,1'-Biphenyl]-4-carbonitrile,  
 4'-[[2-(4-chlorophenyl)-2,3-dihydro-5-(1H-  
 imidazol-1-yl)-3-oxo-4-pyridazinyl]oxy]- (9CI) (CA INDEX NAME)




RN 620617-75-6 CAPLUS

Habte

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[(4'-hydroxy[1,1'-biphenyl]-4-  
 yloxy)-5-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 620617-76-7 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-([1,1'-biphenyl]-4-yloxy)-2-(4-chlorophenyl)-5-(1H-  
 imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 620617-77-8 CAPLUS  
 CN Methanesulfonamide,  
 N-[4'-[[2-(4-chlorophenyl)-2,3-dihydro-5-(1H-imidazol-  
 1-yl)-3-oxo-4-pyridazinyl]oxy][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX  
 NAME)

07/30/2007

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620617-78-9 CAPLUS  
CN Piperazine, 1-acetyl-4-[5-([1,1'-biphenyl]-4-yloxy)-1,6-dihydro-1-(4-methylphenyl)-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 620617-79-0 CAPLUS  
CN Piperazine,  
1-acetyl-4-[5-[(4'-fluoro[1,1'-biphenyl]-4-yl)oxy]-1,6-dihydro-  
1-(4-methylphenyl)-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620617-82-5 CAPLUS  
CN 1-Piperazinecarboxaldehyde,  
4-[5-[(4'-fluoro[1,1'-biphenyl]-4-yl)oxy]-1,6-  
dihydro-1-(4-methylphenyl)-6-oxo-4-pyridazinyl] - (9CI) (CA INDEX NAME)




RN 620617-83-6 CAPLUS  
CN Methanesulfonamide,  
N-[4'-[2-(4-chlorophenyl)-2,3-dihydro-5-(1H-imidazol-  
1-yl)-1,3-oxo-4-pyridazinyl]oxy][1,1'-biphenyl]-3-yl]-  
(9C1) (CA INDEX  
NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620617-80-3 CAPLUS  
CN Formamide, N-[4'-[[2-(4-chlorophenyl)-2,3-dihydro-5-(1H-imidazol-1-yl)-3-oxo-4-pyridazinyl]oxy][1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)




RN 620617-81-4 CAPLUS  
CN 1-Piperazinecarboxaldehyde, 4-[5-([1,1'-biphenyl]-4-yloxy)-1,6-dihydro-1-(4-methylphenyl)-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620617-84-7 CAPLUS  
CN Pipazine,  
1-[5-{[1,1'-biphenyl]-4-yloxy}-1,6-dihydro-1-(4-methylphenyl)-  
6-oxo-4-pyridazinyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 620617-85-8 CAPLUS  
 CN Piperazine, 1-[5-[[4-(4-fluoro[1,1'-biphenyl]-4-yl)oxy]-1,6-dihydro-1-(4-methylphenyl)-6-oxo-4-pyridazinyl]-4-(methylsulfonyl)- {9CI} (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620617-86-9 CAPLUS  
 CN Piperazine, 1-[[1-[(4-chlorophenyl)-5-[(4'-fluoro-2'-(methoxymethoxy)[1,1'-biphenyl]-4-yl]oxy]-1,6-dihydro-6-oxo-4-pyridazinyl]-4-(methylsulfonyl)]- (9CI) (CA INDEX NAME)




RN 620617-87-0 CAPLUS  
 CN Acetamide,  
 N-[[4'-[[2-(4-chlorophenyl)-2,3-dihydro-5-[4-(methylsulfonyl)]-1-

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620617-89-2 CAPLUS  
 CN Piperazine, 1-[[1-[(4-chlorophenyl)-5-[(2',4'-difluoro[1,1'-biphenyl]-4-yl]oxy]-1,6-dihydro-6-oxo-4-pyridazinyl]-4-(methylsulfonyl)]- (9CI) (CA INDEX NAME)




RN 620617-90-5 CAPLUS  
 CN Piperazine, 1-[[1-[(4-chlorophenyl)-5-[(2'-methoxy[1,1'-biphenyl]-4-yl]oxy]-6-oxo-4-pyridazinyl]-4-(methylsulfonyl)]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 piperazinyl]-3-oxo-4-pyridazinyl]oxy]-4-fluoro[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)




RN 620617-88-1 CAPLUS  
 CN Acetamide,  
 N-[[4'-[[2-(4-chlorophenyl)-2,3-dihydro-5-[4-(methylsulfonyl)]-1-piperazinyl]-3-oxo-4-pyridazinyl]oxy][1,1'-biphenyl]-2-yl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620617-91-6 CAPLUS  
 CN Acetamide,  
 N-[[4'-[[2-(4-chlorophenyl)-2,3-dihydro-5-[4-(methylsulfonyl)]-1-piperazinyl]-3-oxo-4-pyridazinyl]oxy]-4-fluoro[1,1'-biphenyl]-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 620617-92-7 CAPLUS  
 CN Piperazine,  
 1-[[1-[(4-chlorophenyl)-5-[(4'-fluoro-2'-methoxy[1,1'-biphenyl]-4-yl]oxy]-1,6-dihydro-6-oxo-4-pyridazinyl]-4-(methylsulfonyl)]- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620617-93-0 CAPLUS  
 CN Acetamide,  
 N-[[4'-[[2-(4-chlorophenyl)-2,3-dihydro-5-[(methylsulfonyl)-1-piperazinyl]-3-oxo-4-pyridazinyl]oxy][1,1'-biphenyl]-3-yl]methyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 620617-97-2 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-[[[1,1'-biphenyl]-4-yloxy]-2-(4-methylphenyl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 620617-98-3 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-[[[4'-fluoro[1,1'-biphenyl]-4-yloxy]-2-(4-methylphenyl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




Habte

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 620617-94-9 CAPLUS  
 CN 1-Piperazinecarboxamide, 4-[5-[[[1,1'-biphenyl]-4-yloxy]-1,6-dihydro-1-(4-methylphenyl)-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 620617-95-0 CAPLUS  
 CN 1-Piperazinecarboxamide, 4-[5-[[[4'-fluoro[1,1'-biphenyl]-4-yloxy]-1,6-dihydro-1-(4-methylphenyl)-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 620617-96-1 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-[[[4'-hydroxy[1,1'-biphenyl]-4-yloxy]-2-(4-methylphenyl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 620617-99-4 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[[[2'-hydroxy[1,1'-biphenyl]-4-yloxy]-5-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 620618-00-0 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[[[4'-fluoro-2'-hydroxy[1,1'-biphenyl]-4-yloxy]-5-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 620618-01-1 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[[[4'-hydroxy[1,1'-biphenyl]-4-yloxy]-5-[4-(2-hydroxyethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

07/30/2007

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-02-2 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[(3'-hydroxy[1,1'-biphenyl]-4-yl)oxy]-5-[4-(2-hydroxyethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 620618-03-3 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[(2'-hydroxy[1,1'-biphenyl]-4-yl)oxy]-5-[4-(2-hydroxyethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-04-4 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[(4'-fluoro-2'-hydroxy[1,1'-biphenyl]-4-yl)oxy]-5-[4-(2-hydroxyethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 620618-05-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[(4'-fluoro-2'-hydroxy[1,1'-biphenyl]-4-yl)oxy]-5-[4-(2-hydroxyethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-06-6 CAPLUS  
CN Piperazine, 1-acetyl-4-[1-(4-chlorophenyl)-5-[(4'-fluoro-2'-hydroxy[1,1'-biphenyl]-4-yl)oxy]-1,6-dihydro-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 620618-07-7 CAPLUS  
CN Piperazine, 1-acetyl-4-[1-(4-chlorophenyl)-5-[(4'-hydroxy[1,1'-biphenyl]-4-yl)oxy]-1,6-dihydro-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-08-8 CAPLUS  
CN Piperazine, 1-acetyl-4-[1-(4-chlorophenyl)-5-[(4'-fluoro-2'-hydroxy[1,1'-biphenyl]-4-yl)oxy]-1,6-dihydro-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 620618-09-9 CAPLUS  
CN Piperazine, 1-acetyl-4-[1-(4-chlorophenyl)-5-[(4'-fluoro-2'-hydroxy[1,1'-biphenyl]-4-yl)oxy]-1,6-dihydro-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-10-2 CAPLUS  
CN Piperazine,  
1-acetyl-4-[[5-[(4'-fluoro-2'-hydroxy[1,1'-biphenyl]-4-yl)oxy]-  
1,6-dihydro-1-(4-methylphenyl)-6-oxo-4-pyridazinyl]-1H-imidazol-1-yl]-2-(4-chlorophenyl)-3(2H)-pyridazinone (9CI) (CA INDEX NAME)




RN 620618-11-3 CAPLUS  
CN 3(2H)-Pyridazinone, 2-[(4-chlorophenyl)-4-[[4'-fluoro-2'-hydroxy[1,1'-biphenyl]-4-yl)oxy]-5-[[4-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl]-1,6-dihydro-6-oxo-4-pyridazinyl]-4-(cyclopropylcarbonyl)-1H-imidazol-1-yl]-2-(4-chlorophenyl)-3(2H)-pyridazinone (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-14-6 CAPLUS  
CN Piperazine,  
1-acetyl-4-[[5-[(4'-fluoro-2'-methoxy[1,1'-biphenyl]-4-yl)oxy]-  
1,6-dihydro-1-(4-methylphenyl)-6-oxo-4-pyridazinyl]-1H-imidazol-1-yl]-2-(4-chlorophenyl)-3(2H)-pyridazinone (9CI) (CA INDEX NAME)




RN 620618-15-7 CAPLUS  
CN 3(2H)-Pyridazinone, 4-[[[1,1'-biphenyl]-4-yl]oxy]-2-(4-chlorophenyl)-5-[[4-methyl-1H-imidazol-1-yl]-1,6-dihydro-6-oxo-4-pyridazinyl]-4-(cyclopropylcarbonyl)-1H-imidazol-1-yl]-2-(4-chlorophenyl)-3(2H)-pyridazinone (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-12-4 CAPLUS  
CN Piperazine, 1-acetyl-4-[[1-(4-chlorophenyl)-5-[[4'-fluoro-2'-methoxy[1,1'-biphenyl]-4-yl)oxy]-1,6-dihydro-6-oxo-4-pyridazinyl]-1,6-dihydro-6-oxo-4-pyridazinyl]-4-(cyclopropylcarbonyl)-1H-imidazol-1-yl]-2-(4-chlorophenyl)-3(2H)-pyridazinone (9CI) (CA INDEX NAME)




RN 620618-13-5 CAPLUS  
CN Piperazine,  
1-[[1-(4-chlorophenyl)-5-[[4'-fluoro-2'-methoxy[1,1'-biphenyl]-4-yl)oxy]-1,6-dihydro-6-oxo-4-pyridazinyl]-4-(cyclopropylcarbonyl)-1H-imidazol-1-yl]-2-(4-chlorophenyl)-3(2H)-pyridazinone (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 620618-16-8 CAPLUS  
CN 3(2H)-Pyridazinone, 4-[[[1,1'-biphenyl]-4-yl]oxy]-5-[[5-chloro-2-methyl-1H-imidazol-1-yl]-2-(4-chlorophenyl)-1,6-dihydro-6-oxo-4-pyridazinyl]-4-(cyclopropylcarbonyl)-1H-imidazol-1-yl]-2-(4-chlorophenyl)-3(2H)-pyridazinone (9CI) (CA INDEX NAME)




RN 620618-17-9 CAPLUS  
CN 3(2H)-Pyridazinone, 4-[[[1,1'-biphenyl]-4-yl]oxy]-2-(4-chlorophenyl)-5-[[4-methyl-1H-imidazol-1-yl]-1,6-dihydro-6-oxo-4-pyridazinyl]-4-(cyclopropylcarbonyl)-1H-imidazol-1-yl]-2-(4-chlorophenyl)-3(2H)-pyridazinone (9CI) (CA INDEX NAME)




RN 620618-18-0 CAPLUS  
CN 3(2H)-Pyridazinone,  
4-[[[1,1'-biphenyl]-4-yl]oxy]-5-[[4,5-bis(hydroxymethyl)-1H-1,2,3-triazol-1-yl]-2-(4-chlorophenyl)-1,6-dihydro-6-oxo-4-pyridazinyl]-4-(cyclopropylcarbonyl)-1H-imidazol-1-yl]-2-(4-chlorophenyl)-3(2H)-pyridazinone (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-19-1 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-([1,1'-biphenyl]-4-yloxy)-2-(4-chlorophenyl)-5-([1,2,3-triazol-1-yl]-1H-1,2,3-triazol-1-yl)- (9CI) (CA INDEX NAME)




RN 620618-20-4 CAPLUS  
 CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[5-([1,1'-biphenyl]-4-yloxy)-1-(4-chlorophenyl)-1,6-dihydro-6-oxo-4-pyridazinyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-21-5 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-([1,1'-biphenyl]-4-yloxy)-2-(4-chlorophenyl)-5-([1,2,3-triazol-1-yl]-1H-1,2,3-triazol-1-yl)- (9CI) (CA INDEX NAME)




RN 620618-22-6 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-([1,1'-biphenyl]-4-yloxy)-2-(4-chlorophenyl)-5-([1,2,3-triazol-1-yl]-1H-1,2,3-triazol-1-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-23-7 CAPLUS  
 CN 1H-1,2,3-Triazole-5-carboxylic acid, 1-[5-([1,1'-biphenyl]-4-yloxy)-1-(4-chlorophenyl)-1,6-dihydro-6-oxo-4-pyridazinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 620618-24-8 CAPLUS  
 CN 3(2H)-Pyridazinone, 5-[4-(bromomethyl)-1H-1,2,3-triazol-1-yl]-2-(4-chlorophenyl)-4-[(4'-fluoro[1,1'-biphenyl]-4-yl)oxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-25-9 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[(4'-fluoro[1,1'-biphenyl]-4-yl)oxy]-5-[4-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl]- (9CI) (CA INDEX NAME)




RN 620618-26-0 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[(4'-fluoro[1,1'-biphenyl]-4-yl)oxy]-5-[5-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-27-1 CAPLUS  
 CN 3(2H)-Pyridazinone,  
 2-(4-chlorophenyl)-4-[(2',4'-difluoro[1,1'-biphenyl]-4-yl)oxy]-5-[4-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl]- (9CI) (CA INDEX NAME)




RN 620618-28-2 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[(4'-fluoro-2''-(methoxymethoxy)[1,1'-biphenyl]-4-yl)oxy]-5-[4-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-31-7 CAPLUS  
 CN Acetamide, N-[4'-[2-(4-chlorophenyl)-2,3-dihydro-5-(1H-imidazol-1-yl)-3-oxo-4-pyridazinyl]oxy][1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)




RN 620618-32-8 CAPLUS  
 CN 1-Piperazinecarboxylic acid,  
 4-[5-[(1,1'-biphenyl)-4-yl]oxy]-1,6-dihydro-1-(4-methylphenyl)-6-oxo-4-pyridazinyl]-, 1,1-dimethylethyl ester (9CI)  
 (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-29-3 CAPLUS  
 CN 3(2H)-Pyridazinone,  
 2-(4-chlorophenyl)-4-[(2',4'-difluoro[1,1'-biphenyl]-4-yl)oxy]-5-[5-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl]- (9CI) (CA INDEX NAME)




RN 620618-30-6 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[(4'-fluoro-2''-(methoxymethoxy)[1,1'-biphenyl]-4-yl)oxy]-5-[5-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-33-9 CAPLUS  
 CN 1-Piperazinecarboxylic acid,  
 4-[5-[(4'-fluoro[1,1'-biphenyl]-4-yl)oxy]-1,6-dihydro-1-(4-methylphenyl)-6-oxo-4-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 620618-34-0 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[(5'-fluoro-2''-methyl[1,1'-biphenyl]-4-yl)oxy]-5-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-35-1 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-[(3'-amino[1,1'-biphenyl]-4-yl)oxy]-2-(4-chlorophenyl)-5-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 620618-36-2 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[(4'-fluoro[1,1'-biphenyl]-4-yl)oxy]-5-[4-(2-hydroxyethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-39-5 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-5-(1H-imidazol-1-yl)-4-[[2-(methoxymethoxy)[1,1'-biphenyl]-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 620618-40-8 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[(4'-fluoro-2'-(methoxymethoxy)[1,1'-biphenyl]-4-yl)oxy]-5-(1H-imidazol-1-yl)- (9CI)  
 (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-37-3 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[(4'-fluoro[1,1'-biphenyl]-4-yl)oxy]-5-[4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]- (9CI) (CA INDEX NAME)




RN 620618-38-4 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-5-(1H-imidazol-1-yl)-4-[4-(3-pyridinyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-41-9 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-5-[4-(2-hydroxyethyl)-1-piperazinyl]-4-[4-(3-pyridinyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 620618-42-0 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-[4-(6-amino-3-pyridinyl)phenoxy]-2-(4-chlorophenyl)-5-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-43-1 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-[(3'-amino[1,1'-biphenyl]-4-yl)oxy]-2-(4-chlorophenyl)-5-[4-(2-hydroxyethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 620618-44-2 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[[2'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]oxy]-5-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-47-5 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-5-[4-(2-hydroxyethyl)-1-piperazinyl]-4-[[2'-(methoxymethoxy)[1,1'-biphenyl]-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 620618-48-6 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[[4'-fluoro-2'-(methoxymethoxy)[1,1'-biphenyl]-4-yl]oxy]-5-[4-(2-hydroxyethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-45-3 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-[[3'-(aminomethyl)[1,1'-biphenyl]-4-yl]oxy]-2-(4-chlorophenyl)-5-[4-(2-hydroxyethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 620618-46-4 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-5-[4-(2-hydroxyethyl)-1-piperazinyl]-4-[[2'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]oxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-49-7 CAPLUS  
 CN [1,1'-Biphenyl]-3-carboxamide, 4'-[[2-(4-chlorophenyl)-2,3-dihydro-5-[4-(2-hydroxyethyl)-1-piperazinyl]-3-oxo-4-pyridazinyl]oxy]-4-fluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 620618-51-1 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[[2'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]oxy]-5-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-52-2 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[(2',4'-difluoro[1,1'-biphenyl]-4-yl)oxy]-5-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 620618-53-3 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-5-(1H-imidazol-1-yl)-4-[(2'-methoxy[1,1'-biphenyl]-4-yl)oxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-54-4 CAPLUS  
CN 3(2H)-Pyridazinone, 4-[(3'-amino-4'-fluoro[1,1'-biphenyl]-4-yl)oxy]-2-(4-chlorophenyl)-5-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 620618-55-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-5-[4-(2-hydroxyethyl)-1-piperazinyl]-4-[(2'-methyl[1,1'-biphenyl]-4-yl)oxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-56-6 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-5-[4-(2-hydroxyethyl)-1-piperazinyl]-4-[(2'-methoxy[1,1'-biphenyl]-4-yl)oxy]- (9CI) (CA INDEX NAME)




RN 620618-57-7 CAPLUS  
CN 3(2H)-Pyridazinone, 4-[(2'-amino[1,1'-biphenyl]-4-yl)oxy]-2-(4-chlorophenyl)-5-[4-(2-hydroxyethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-58-8 CAPLUS  
CN Acetamide,  
N-[4'-[(2-(4-chlorophenyl)-2,3-dihydro-5-[4-(2-hydroxyethyl)-1-piperazinyl]-3-oxo-4-pyridazinyl]oxy][1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)




RN 620618-59-9 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-5-[4-(2-hydroxyethyl)-1-piperazinyl]-4-[(3'-(hydroxymethyl)[1,1'-biphenyl]-4-yl)oxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-60-2 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-[(3'-acetyl[1,1'-biphenyl]-4-yl)oxy]-2-(4-chlorophenyl)-5-[4-(2-hydroxyethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 620618-61-3 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-[(3'-amino-4'-fluoro[1,1'-biphenyl]-4-yl)oxy]-2-(4-chlorophenyl)-5-[4-(2-hydroxyethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-64-6 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[(3'-(hydroxymethyl)[1,1'-biphenyl]-4-yl)oxy]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 620618-65-7 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[(4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl)oxy]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-62-4 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-[(4'-amino[1,1'-biphenyl]-4-yl)oxy]-2-(4-chlorophenyl)-5-[4-(2-hydroxyethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 620618-63-5 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[(2'-(hydroxymethyl)[1,1'-biphenyl]-4-yl)oxy]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-66-8 CAPLUS  
 CN Acetamide, N-[4'-[[2-(4-chlorophenyl)-2,3-dihydro-3-oxo-5-(1-piperazinyl)-4-pyridazinyl]oxy]-4-fluoro[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)




RN 620618-67-9 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-[(2'-(aminomethyl)[1,1'-biphenyl]-4-yl)oxy]-2-(4-chlorophenyl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-68-0 CAPLUS  
CN 3(2H)-Pyridazinone, 4-[(3'-(aminomethyl)-4'-fluoro[1,1'-biphenyl]-4-yloxy]-2-(4-chlorophenyl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 620618-69-1 CAPLUS  
CN Acetamide,  
N-[[4'-[[2-(4-chlorophenyl)-2,3-dihydro-3-oxo-5-(1-piperazinyl)-4-pyridazinyl]oxy][1,1'-biphenyl]-2-yl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-72-6 CAPLUS  
CN Piperazine, 1-acetyl-4-[[1-(4-chlorophenyl)-5-[[4'-fluoro-2'-(methoxymethoxy)[1,1'-biphenyl]-4-yl]oxy]-1,6-dihydro-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 620618-73-7 CAPLUS  
CN Piperazine, 1-acetyl-4-[[1-(4-chlorophenyl)-5-[[4'-fluoro-2'-(methoxymethoxy)[1,1'-biphenyl]-4-yl]oxy]-1,6-dihydro-6-oxo-4-pyridazinyl]- (9CI)  
(CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-70-4 CAPLUS  
CN Acetamide,  
N-[[4'-[[2-(4-chlorophenyl)-2,3-dihydro-3-oxo-5-(1-piperazinyl)-4-pyridazinyl]oxy]-4-fluoro[1,1'-biphenyl]-3-yl]methyl]- (9CI) (CA INDEX NAME)




RN 620618-71-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[[4'-fluoro-2'-(methoxymethoxy)[1,1'-biphenyl]-4-yl]oxy]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-74-8 CAPLUS  
CN Piperazine, 1-acetyl-4-[[1-(4-chlorophenyl)-5-[[4'-fluoro-3'-(methoxymethoxy)[1,1'-biphenyl]-4-yl]oxy]-1,6-dihydro-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 620618-75-9 CAPLUS  
CN 3(2H)-Pyridazinone,  
2-(4-chlorophenyl)-4-[[2',4'-difluoro[1,1'-biphenyl]-4-yl]oxy]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-76-0 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[(2'-methoxy[1,1'-biphenyl]-4-yl)oxy]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 620618-77-1 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[(4'-fluoro-2'-methoxy[1,1'-biphenyl]-4-yl)oxy]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-78-2 CAPLUS  
 CN Acetamide,  
 N-[[4'-[2-(4-chlorophenyl)-2,3-dihydro-3-oxo-5-(1-piperazinyl)-4-pyridazinyl]oxy][1,1'-biphenyl]-3-yl]methyl]- (9CI) (CA INDEX NAME)




RN 620618-79-3 CAPLUS  
 CN Piperazine, 1-[1-(4-chlorophenyl)-5-[(4'-fluoro[1,1'-biphenyl]-4-yl)oxy]-1,6-dihydro-6-oxo-4-pyridazinyl]-4-(cyclopropylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-80-6 CAPLUS  
 CN Piperazine, 1-[1-(4-chlorophenyl)-5-[(2',4'-difluoro[1,1'-biphenyl]-4-yl)oxy]-1,6-dihydro-6-oxo-4-pyridazinyl]-4-(cyclopropylcarbonyl)- (9CI) (CA INDEX NAME)




RN 620618-81-7 CAPLUS  
 CN Piperazine, 1-[1-(4-chlorophenyl)-5-[(4'-fluoro-3'-(hydroxymethyl)[1,1'-biphenyl]-4-yl)oxy]-1,6-dihydro-6-oxo-4-pyridazinyl]-4-(cyclopropylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-82-8 CAPLUS  
 CN Piperazine, 1-[1-(4-chlorophenyl)-5-[(4'-fluoro-2'-(methoxymethoxy)[1,1'-biphenyl]-4-yl)oxy]-1,6-dihydro-6-oxo-4-pyridazinyl]-4-(cyclopropylcarbonyl)- (9CI) (CA INDEX NAME)




RN 620618-83-9 CAPLUS  
 CN Piperazine, 1-[1-(4-chlorophenyl)-5-[(4'-fluoro-3'-(hydroxymethyl)[1,1'-biphenyl]-4-yl)oxy]-1,6-dihydro-6-oxo-4-pyridazinyl]-4-(cyclopropylcarbonyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-84-0 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[1-(4-chlorophenyl)-1,6-dihydro-6-oxo-5-[4-(2-pyridinyl)phenoxy]-4-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 620618-85-1 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[5-[(2',4'-difluoro[1,1'-biphenyl]-4-yl)oxy]-1,6-dihydro-1-(4-methylphenyl)-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-86-2 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[1,6-dihydro-1-(4-methylphenyl)-6-oxo-5-[4-(5-pyrimidinyl)phenoxy]-4-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 620618-87-3 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[5-[(4'-fluoro-2'-(methoxymethoxy)[1,1'-biphenyl]-4-yl)oxy]-1,6-dihydro-1-(4-methylphenyl)-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-88-4 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[1-(4-chlorophenyl)-5-[(2',4'-difluoro[1,1'-biphenyl]-4-yl)oxy]-1,6-dihydro-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 620618-89-5 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[1-(4-chlorophenyl)-5-[(4'-fluoro-2'-methyl[1,1'-biphenyl]-4-yl)oxy]-1,6-dihydro-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-90-8 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[1-(4-chlorophenyl)-5-[(2'-fluoro[1,1'-biphenyl]-4-yl)oxy]-1,6-dihydro-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 620618-91-9 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[1-(4-chlorophenyl)-1,6-dihydro-5-[(2'-methoxy[1,1'-biphenyl]-4-yl)oxy]-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-92-0 CAPLUS  
 CN Piperazine,  
 1-acetyl-4-[[1-(4-chlorophenyl)-1,6-dihydro-5-[(2'-methoxy[1,1'-  
 biphenyl]-4-yl)oxy]-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 620618-93-1 CAPLUS  
 CN Piperazine,  
 1-acetyl-4-[[1-(4-chlorophenyl)-1,6-dihydro-5-[(3'-methoxy[1,1'-  
 biphenyl]-4-yl)oxy]-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-96-4 CAPLUS  
 CN Acetamide, N-[4'-[[5-(4-acetyl-1-piperazinyl)-2-(4-chlorophenyl)-2,3-  
 dihydro-3-oxo-4-pyridazinyl]oxy][1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX  
 NAME)




RN 620618-97-5 CAPLUS  
 CN Acetamide, N-[4'-[[5-(4-acetyl-1-piperazinyl)-2-(4-chlorophenyl)-2,3-  
 dihydro-3-oxo-4-pyridazinyl]oxy]-4-fluoro[1,1'-biphenyl]-3-yl]- (9CI)  
 (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-94-2 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[1-(4-chlorophenyl)-1,6-dihydro-5-[[3'-  
 (hydroxymethyl)[1,1'-biphenyl]-4-yl]oxy]-6-oxo-4-pyridazinyl]- (9CI) (CA  
 INDEX NAME)




RN 620618-95-3 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[1-(4-chlorophenyl)-1,6-dihydro-5-[[3'-  
 (hydroxymethyl)[1,1'-biphenyl]-4-yl]oxy]-6-oxo-4-pyridazinyl]- (9CI) (CA  
 INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620618-98-6 CAPLUS  
 CN Acetamide, N-[4'-[[5-(4-acetyl-1-piperazinyl)-2-(4-chlorophenyl)-2,3-  
 dihydro-3-oxo-4-pyridazinyl]oxy][1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX  
 NAME)




RN 620618-99-7 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[1-(4-chlorophenyl)-5-[[4'-fluoro-3'-  
 (methylsulfonylamino)[1,1'-biphenyl]-4-yl]oxy]-1,6-dihydro-6-oxo-4-  
 pyridazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620619-00-3 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[1-(4-chlorophenyl)-1,6-dihydro-5-[[3'-((methylsulfonyl)amino)[1,1'-biphenyl]-4-yl]oxy]-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 620619-01-4 CAPLUS  
 CN Acetamide, N-[[4'-[[5-(4-acetyl-1-piperazinyl)-2-(4-chlorophenyl)-2,3-dihydro-3-oxo-4-pyridazinyl]oxy][1,1'-biphenyl]-2-yl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620619-04-7 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[5-[[3'-(aminomethyl)-4'-fluoro[1,1'-biphenyl]-4-yl]oxy]-1-(4-chlorophenyl)-1,6-dihydro-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 620619-05-8 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[5-[[3'-(aminomethyl)-4'-fluoro[1,1'-biphenyl]-4-yl]oxy]-1-(4-chlorophenyl)-1,6-dihydro-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620619-02-5 CAPLUS  
 CN Acetamide, N-[[4'-[[5-(4-acetyl-1-piperazinyl)-2-(4-chlorophenyl)-2,3-dihydro-3-oxo-4-pyridazinyl]oxy]-4-fluoro[1,1'-biphenyl]-3-yl]methyl]- (9CI) (CA INDEX NAME)




RN 620619-03-6 CAPLUS  
 CN Acetamide, N-[[4'-[[5-(4-acetyl-1-piperazinyl)-2-(4-chlorophenyl)-2,3-dihydro-3-oxo-4-pyridazinyl]oxy][1,1'-biphenyl]-3-yl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620619-06-9 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[5-[[3'-(aminomethyl)-4'-fluoro[1,1'-biphenyl]-4-yl]oxy]-1-(4-chlorophenyl)-1,6-dihydro-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)




IT 620619-29-6, 4-(4-Bromophenoxy)-2-(4-chlorophenyl)-5-(1-piperazinyl)-3(2H)-pyridazinone 620619-34-3, tert-Butyl 4-[5-[[4'-hydroxy-4-biphenyl-4-yl]oxy]-1-(4-methylphenyl)-6-oxo-1,6-dihydro-4-pyridazinyl]-1-piperazine carboxylate 620619-37-6, 2-(4-Chlorophenyl)-4-[[4'-fluoro-4-biphenyl]oxy]-5-(4-hydroxypiperidin-1-yl)-3(2H)-pyridazinone 620619-39-8, 5-Chloro-4-[[4'-fluoro-4-biphenyl]oxy]-2-(4-chlorophenyl)-3(2H)-pyridazinone  
 RL RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of phenylpyridazinones as tyrosyl oxidase inhibitors for treatment of fibrosis)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 RN 620619-29-6 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-(4-bromophenoxy)-2-(4-chlorophenyl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 620619-34-3 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[1,6-dihydro-5-[(4'-hydroxy[1,1'-biphenyl]-4-yl)oxy]-1-(4-methylphenyl)-6-oxo-4-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 620619-37-6 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(4-chlorophenyl)-4-[(4'-fluoro[1,1'-biphenyl]-4-yl)oxy]-5-(4-hydroxy-1-piperidinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 620619-39-8 CAPLUS  
 CN 3(2H)-Pyridazinone, 5-chloro-2-(4-chlorophenyl)-4-[(4'-fluoro[1,1'-biphenyl]-4-yl)oxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2003:570966 CAPLUS  
 DOCUMENT NUMBER: 139:117432  
 TITLE: Substituted pyridazinones as inhibitors of p38 kinase  
 INVENTOR(S): Hepperle, Michael; Jerome, Kevin D.; Walker, John; Selness, Shaun; Devraj, Rajesh  
 PATENT ASSIGNEE(S): Pharmacia Corporation, USA  
 SOURCE: PCT Int. Appl., 177 pp.  
 CODEN: PIXX22  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003059891	A1	20030724	WO 2003-US1780	20030121
W1	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GO, GM, ML, MR, NE, SN, TD, TG			
CA 2474239	A1	20030724	CA 2003-2474239	20030121
AU 2003209321	A1	20030730	AU 2003-209321	20030121
US 2004142932	A1	20040722	US 2003-347853	20030121
EP 1470112	A1	20041027	EP 2003-707475	20030121
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003006988	A	20041123	BR 2003-6988	20030121
JP 200519895	T	20050707	JP 2003-559955	20030121
MX 2004PA06781	A	20041110	MX 2004-PA6781	20040712
US 2005256122	A1	20051117	US 2005-69471	20050301
PRIORITY APPLN. INFO.:			US 2002-350741P	P 20020118
			US 2002-355044P	P 20020207
			US 2003-347853	BI 20030121
			WO 2003-US1780	W 20030121

OTHER SOURCE(S): MARPAT 139:117432  
 GI



Habte

L4 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB Title compds. I (R1 = H, halo, NO2, alkyl, carboxaldehyde, etc.; R2 = H, OH, halo, sulfonyloxy, etc.; R3 = H, halo, alkoxy, carbonyl, arylalkoxy, carbonyl, etc.; R5 = H, (hetero)aryl, arylalkyl, arylthioalkyl, etc.) are prepared. For instance, mucobromic acid is reacted with benzyl hydrazine-2HCl (6N HCl, room temperature) to give 2-benzyl-4,5-dibromopyridazin-3(2H)-one. Selected example compds. exhibit IC50 =

60-80 μM in the p38-α kinase assay. I are useful for the treatment of, e.g., Alzheimer's disease and peripheral neuropathy.


IT 565157-32-6P, 2-(2,6-Dichlorophenyl)-4-phenoxy-5-(2-phenylethoxy)pyridazin-3(2H)-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(substituted pyridazinones as inhibitors of p38 kinase)

RN 565157-32-6 CAPLUS

CN 3(2H)-Pyridazinone, 2-(2,6-dichlorophenyl)-4-phenoxy-5-(2-phenylethoxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT


07/30/2007

L4 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2001:772163 CAPLUS  
 DOCUMENT NUMBER: 135:318510  
 TITLE: Preparation of arylpyridazinones as prostaglandin endoperoxide H synthase biosynthesis inhibitors  
 INVENTOR(S): Black, Lawrence A.; Basha, Anwar; Kolasa, Teodorzyj; Kort, Michael E.; Liu, Huaqing; McCarty, Catherine M.; Patel, Meena; Rohde, Jeffrey J.; Coghlan, Michael J.; Stewart, Andrew O.  
 PATENT ASSIGNEE(S): Abbott Laboratories, USA  
 SOURCE: U.S., 129 pp., Cont.-in-part of U.S. Ser. No. 261,872, abandoned.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6307047	B1	20011023	US 1999-427768	19991027
TR 200000478	T2	20020422	TR 2000-200000478	19980810
CA 2347982	A1	20000504	CA 1999-2347982	19991027
WO 2000024719	A1	20000504	WO 1999-US25234	19991027
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RM: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9965230	A	20000515	AU 1999-65230	19991027
AU 773237	B2	20040520		
EP 1124804	A1	20010822	EP 1999-953259	19991027
EP 1124804	B1	20050824		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9914858	A	20020205	BR 1999-14858	19991027
TR 200101765	T2	20020221	TR 2001-200101765	19991027
HU 200105248	A2	20020729	HU 2001-5248	19991027
JP 2003512292	T	20031002	JP 2000-578889	19991027
AT 302759	T	20050915	AT 1999-953259	19991027
ES 2249919	T3	20060401	ES 1999-953259	19991027
ZA 200100310	A	20020723	ZA 2001-3310	20010423
NO 2001002061	A	20010627	NO 2001-2061	20010426
NO 318623	B1	20050418		
BG 105523	A	20011231	BG 2001-105523	20010519
US 2002013318	A1	20020131	US 2001-871195	20010531
US 2002028938	A1	20020307	US 2001-870838	20010531
HK 1041876	A1	20060624	HK 2002-101207	20020219
US 2003225276	A1	20031204	US 2003-417959	20030417
US 7001895	B2	20060221		
US 2004158064	A1	20040812	US 2003-464928	20030619


L4 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 US 7115591 B2 20061003  
 PRIORITY APPLN. INFO.: US 1997-56733P P 19970822  
 US 1998-129570 B2 19980805  
 US 1998-137457 B2 19980820  
 US 1998-179605 B2 19981027  
 US 1999-261872 B2 19990303  
 US 1997-917023 A 19970822  
 US 1999-298490 A 19990423  
 US 1999-427768 A 19991027  
 WO 1999-US25234 W 19991027  
 US 2001-870838 B3 20010531  
 US 2001-871195 B2 20010531

OTHER SOURCE(S): MARPAT 135:318510  
 GI




AB The title compds. [I; X = O, S, NR4, etc.; R4 = alkyl, alkenyl, cycloalkyl, etc.; R = H, alkyl, alkenyl, etc.; at least one of R1-R3 = II-III (wherein X1 = SO2, SO(NR10), SO, etc.; R9 = alkyl, alkenyl, alkynyl, etc.; X2 = H, halo, alkyl, etc.; R10 = H, alkyl, cycloalkyl); the remaining two of the groups of R1-R3 = H, OH, hydroxyalkyl, etc.] which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2), and therefore are useful in

L4 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 treating pain, fever, inflammation, rheumatoid arthritis, and osteoarthritis, were prep'd. Thus, oxidn. of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (prepn. given) with MeCO3H in CH2Cl2 afforded 86% I [X = O; R = PhCH2; R1 = 4-FC6H4; R2 = 4-(MeSO2)C6H4; R3 = H], which showed IC50 of 0.014 µM against COX-2. COX-2 is the inducible isoform assoc'd. with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal tract and the kidneys. The selectivity of the compds. I for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).  
 IT 221026-45-5P 221026-46-6P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (target compound; preparation of arylpyridazinones as prostaglandin endoperoxide H synthase biosynthesis inhibitors)  
 RN 221026-45-5 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-(4-fluorophenoxy)-2-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221026-46-6 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(3,4-difluorophenyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




IT 221026-47-7P 221026-48-8P 221026-49-9P  
 221028-72-4P 221028-73-5P 221029-36-3P  
 221029-37-4P 221029-39-6P 221029-45-4P  
 221029-92-1P 221029-95-4P 221030-14-4P  
 221030-18-8P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (target compound; preparation of arylpyridazinones as prostaglandin endoperoxide H synthase biosynthesis inhibitors)  
 RN 221026-47-7 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(3-bromophenyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221026-48-8 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(3,5-difluorophenyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 221026-49-9 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(3-chlorophenyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221028-72-4 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-(4-chlorophenoxy)-2-(3,4-difluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 221028-73-5 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-(4-bromophenoxy)-2-(3,4-difluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221029-36-3 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(3-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-4-phenoxy- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 221029-37-4 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(3-chlorophenyl)-4-[3-(dimethylamino)phenoxy]-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221029-39-6 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(3-chlorophenyl)-4-(4-methoxyphenoxy)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221029-45-4 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(3,4-difluorophenyl)-5-[3-fluoro-4-(methylsulfonyl)phenyl]-4-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 221029-92-1 CAPLUS  
 CN Benzenesulfonamide, 4-[5-(4-fluorophenoxy)-1,6-dihydro-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 221029-95-4 CAPLUS  
 CN Benzenesulfonamide, 4-[1-(3,4-difluorophenyl)-5-(4-fluorophenoxy)-1,6-dihydro-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 221030-14-4 CAPLUS  
 CN Benzenesulfonamide, 4-[1-(3,4-difluorophenyl)-5-(4-fluorophenoxy)-1,6-dihydro-6-oxo-4-pyridazinyl]-2-fluoro- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 221030-18-8 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(3-chlorophenyl)-4-(3-fluorophenoxy)-5-(4-methylsulfonylphenyl)- (9CI) (CA INDEX NAME)






REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

US 1998-129570 B2 19980805  
 US 1998-137457 B2 19980820  
 WO 1999-US25234 W 19991027

OTHER SOURCE(S): MARPAT 132:321867  
 GI



AB The title compds. [I; X = O, S, NR4, etc.; R4 = alkyl, alkenyl, cycloalkyl, etc.; R = H, alkyl, alkenyl, etc.; at least one of R1-R3 = II-III (wherein X1 = SO2, SO(NR10), SO, etc.; R9 = alkyl, alkenyl, alkenyl, etc.; X2 = H, halo, alkyl, etc.; R10 = H, alkyl, cycloalkyl); the remaining two of the groups of R1-R3 = H, OH, hydroxyalkyl, etc.] which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2), and therefore are useful in treating pain, fever, inflammation, rheumatoid arthritis, osteoarthritis, adhesions, and cancer, were prepared. Thus, oxidation of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (preparation given) with MeCO3H in CH2Cl2 afforded 86% I [X = O; R = PhCH2; R1 = 4-FC6H4; R2 =

4-(MeSO2)C6H4; R3 = H], which showed 0.014  $\mu$ M against COX-2. COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal tract and the kidneys. The selectivity of the compds. I for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

IT 221026-45-5P 221026-46-6P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (target compound; preparation of arylpyridazinones as prostaglandin endoperoxide H synthase biosynthesis inhibitors)

RN 221026-45-5 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-(4-fluorophenoxy)-2-(4-fluorophenyl)-5-[4-(methylsulfonylphenyl)- (9CI) (CA INDEX NAME)

Habe

L4 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 2000:291005 CAPLUS  
 DOCUMENT NUMBER: 132:321867  
 TITLE: Preparation of arylpyridazinones as prostaglandin endoperoxide H synthase biosynthesis inhibitors  
 INVENTOR(S): Black, Lawrence A.; Bashra, Anwer; Kolasa, Tadeusz; Kort, Michael E.; Liu, Huaqing; McCarty, Catherine M.;

Patel, Meena V.; Rohde, Jeffrey J.; Coghlan, Michael J.; Stewart, Andrew O.  
 PATENT ASSIGNEE(S): Abbott Laboratories, USA  
 SOURCE: PCT Int. Appl., 477 pp.  
 CODEN: PIXXD2


DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000024719	A1	20000504	WO 1999-US25234	19991027
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BP, DJ, CP, CQ, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2347982	A1	20000504	CA 1999-2347982	19991027
AU 9965210	A	20000515	AU 1999-65210	19991027
AU 773217	B2	20040520		
EP 1124804	A1	20010822	EP 1999-953259	19991027
EP 1124804	B1	20050824		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6307047	B1	20011023	US 1999-427768	19991027
BR 9914858	A	20020205	BR 1999-14858	19991027
JP 2003512292	T	20030402	JP 2000-578289	19991027
AT 302759	T	20050915	AT 1999-953259	19991027
ZA 2001003110	A	20020723	ZA 2001-3310	20010423
NO 2001002061	A	20010627	NO 2001-2061	20010426
NO 318623	B1	20050418		
MX 2001P04247	A	20010910	MX 2001-PA4247	20010427
BO 105521	A	20011121	BO 2001-105521	20010519
HK 1041876	A1	20060623	HK 2002-101207	20020219
PRIORITY APPLN. INFO.:			US 1998-179605	A 19981027
			US 1999-261872	A 19990303
			US 1999-298490	A 19990423
			US 1999-427768	A 19991027
			US 1997-56733P	P 19970822

L4 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 221026-46-6 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(3,4-difluorophenyl)-4-(4-fluorophenoxy)-5-(4-methylsulfonylphenyl)- (9CI) (CA INDEX NAME)




IT 221026-47-7P 221026-48-8P 221026-49-9P  
 221028-72-4P 221028-73-5P 221029-36-3P  
 221029-37-4P 221029-39-6P 221029-45-4P  
 221029-92-1P 221029-95-4P 221030-14-4P  
 221030-18-8P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (target compound; preparation of arylpyridazinones as prostaglandin endoperoxide H synthase biosynthesis inhibitors)


RN 221026-47-7 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(3-bromophenyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonylphenyl)- (9CI) (CA INDEX NAME)

07/30/2007


L4 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 221026-48-8 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-[(3,5-difluorophenyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]]- (9CI) (CA INDEX NAME)




RN 221026-49-9 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-[(3-chlorophenyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]]- (9CI) (CA INDEX NAME)




RN 221028-72-4 CAPLUS


L4 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 221029-37-4 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-[(3-chlorophenyl)-4-(3-(dimethylamino)phenoxy)-5-[4-(methylsulfonyl)phenyl]]- (9CI) (CA INDEX NAME)




RN 221029-39-6 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-[(3-chlorophenyl)-4-(4-methoxyphenoxy)-5-[4-(methylsulfonyl)phenyl]]- (9CI) (CA INDEX NAME)




RN 221029-45-4 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-[(3,4-difluorophenyl)-5-[3-fluoro-4-(methylsulfonyl)phenyl]-4-(4-fluorophenoxy)]- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 CN 3(2H)-Pyridazinone, 4-[(4-chlorophenoxy)-2-[(3,4-difluorophenyl)-5-[4-(methylsulfonyl)phenyl]]- (9CI) (CA INDEX NAME)




RN 221028-73-5 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-[(4-bromophenoxy)-2-[(3,4-difluorophenyl)-5-[4-(methylsulfonyl)phenyl]]- (9CI) (CA INDEX NAME)




RN 221029-36-3 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-[(3-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-4-phenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 221029-92-1 CAPLUS  
 CN Benzenesulfonamide, 4-[5-(4-fluorophenoxy)-1-[(4-fluorophenyl)-1,6-dihydro-6-oxo-4-pyridazinyl]]- (9CI) (CA INDEX NAME)




RN 221029-95-4 CAPLUS  
 CN Benzenesulfonamide, 4-[1-[(3,4-difluorophenyl)-5-(4-fluorophenoxy)-1,6-dihydro-6-oxo-4-pyridazinyl]]- (9CI) (CA INDEX NAME)




RN 221030-14-4 CAPLUS  
 CN Benzenesulfonamide, 4-[1-[(3,4-difluorophenyl)-5-(4-fluorophenoxy)-1,6-dihydro-6-oxo-4-pyridazinyl]]-2-fluoro- (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 221030-18-8 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(3-chlorophenyl)-4-(3-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT


L4 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 prevention of cell adhesion-related diseases such as inflammation, asthma, rheumatism, arteriosclerosis, allergy, cancer, inflammation disorders, ischemic reperfusion, organ transplant rejection, psoriasis, inflammatory bowel diseases, and burn. Thus, pentane-2,3,4-trione 3-(3-chlorophenylhydrazone) was treated with NaH under ice-cooling and stirred for 30 min, followed by adding dropwise a soln. of phenylthioacetyl chloride in THF, and the resulting mixt. was stirred at room temp. for 12 h to give 6-acetyl-2-(3-chlorophenyl)-5-methyl-4-(phenylthio)-3(2H)-pyridazinone (III). II in vitro inhibited the CHO-Met-Leu-Phe-OH-induced adhesion of human neutrophilic leukocyte to wells of a culture plate with showed IC50 of 0.004  $\mu$ M.

IT 259192-85-3P 259192-86-4P 259192-87-5P  
 259192-88-6P 259192-89-7P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of pyridazinone derivs. as inhibitors of cell adhesion for treatment and prevention of cell adhesion-related diseases)

RN 259192-85-3 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-acetyl-2-(3-chlorophenyl)-5-methyl-4-phenoxy- (9CI) (CA INDEX NAME)



RN 259192-86-4 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-acetyl-4-(4-chlorophenoxy)-2-(3-chlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 259192-87-5 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-acetyl-4-(4-chlorophenoxy)-2-(4-chlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2000:133666 CAPLUS  
 DOCUMENT NUMBER: 132:180587  
 TITLE: Preparation of pyridazinone derivatives as inhibitors of cell adhesion  
 INVENTOR(S): Gotoh, Makoto; Uemoto, Koji; Onishi, Masanobu; Satoh, Akiyuki; Oshita, Yoshitami; Nagamine, Masashi  
 PATENT ASSIGNEE(S): Nihon Nohyaku Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 67 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200009488	A1	20000224	WO 1999-JP4384	19990812
W: AU, CA, CN, KR, US				
RW: CH, DE, FR, GB, IT				
CA 2340230	A1	20000224	CA 1999-2340230	19990812
AU 9951976	A1	20000306	AU 1999-51976	19990812
AU 756275	B2	20030109		
EP 1130015	A1	20010905	EP 1999-937056	19990812
R: CH, DE, FR, GB, IT, LI				
JP 2000119257	A	20000425	JP 1999-229303	19990812
US 6469003	B1	20021022	US 2001-762877	20010214
PRIORITY APPLN. INFO.:			JP 1998-229623	A 19980814
			WO 1999-JP4384	W 19990812

OTHER SOURCE(S): MARPAT 132:180587  
 GI




AB Described are pyridazinone derivs. represented by general formula (I); wherein R1 is optionally substituted Ph or an aromatic heterocyclic group; R2 is optionally substituted alkyl, Ph, aralkyl, an aromatic heterocyclic group, amino, cyclic amino, cyano, carboxyl or the like; R3 is hydrogen, optionally substituted alkyl, Ph or an aromatic heterocyclic group; and R4 is cyano, carbonyl or the like) or medicinally acceptable salts of them; and drug compns. containing the same as the active ingredient for the treatment or


L4 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 259192-88-6 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-acetyl-2-(3-chlorophenyl)-4-(4-fluorophenoxy)-5-methyl- (9CI) (CA INDEX NAME)



RN 259192-89-7 CAPLUS  
 CN 3(2H)-Pyridazinone, 6-acetyl-4-(4-fluorophenoxy)-2-(3-fluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT


L4 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1999:166604 CAPLUS  
 DOCUMENT NUMBER: 130:223284  
 TITLE: Preparation of arylpyridazinones as prostaglandin endoperoxide H synthase biosynthesis inhibitors  
 INVENTOR(S): Black, Lawrence A.; Bashe, Anwer; Kolasa, Teodorzy; Kort, Michael E.; Liu, Huang; McCarty, Catherine M.;  
 PATENT ASSIGNEE(S): Abbott Laboratories, USA  
 SOURCE: PCT Int. Appl., 307 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9910331	A1	19990304	WO 1998-US16479	19980810
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: OH, OM, OS, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2299300	A1	19990304	CA 1998-2299300	19980810
CA 2299300	C	20070417		
CA 2578858	A1	19990304	CA 1998-2578858	19980810
AU 9886976	A	19990316	AU 1998-86976	19980810
AU 741317	B2	20011129		
EP 1007515	A1	20000614	EP 1998-938451	19980810
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
BR 9812127	A	20000718	BR 1998-12127	19980810
TR 200000478	T2	20020422	TR 2000-200000478	19980810
JP 2003516925	T	20030520	JP 2000-507660	19980810
HU 200400909	A2	20040728	HU 2004-909	19980810
HU 200400909	A3	20041028		
IL 133552	A	20051218	IL 1998-133552	19980810
ZA 9807555	A	19990223	ZA 1998-7555	19980810
TW 232216	B	20050511	TW 1998-87113837	19980910
NO 200000863	A	20000222	NO 2000-863	20000222
NO 315423	B1	20030901		
MX 200001850	A	20001030	MX 2000-1850	20000222
BG 104241	A	20001031	BG 2000-104241	20000315
BG 64675	B1	20051130		
PRIORITY APPLN. INFO.:			US 1997-917023	A 19970822
			US 1998-129570	A 19980805
			CA 1998-2299300	A3 19980810
			WO 1998-US16479	W 19980810

L4 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 221026-46-6 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(3,4-difluorophenyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




IT 221026-47-7P 221026-48-8P 221026-49-9P  
 221028-72-4P 221028-73-5P 221029-36-3P  
 221029-37-4P 221029-39-6P 221029-45-4P  
 221029-92-1P 221029-95-4P 221030-14-4P  
 221030-18-8P  
 RL: BAC (Biological activity or effector, except adverse); BSU  
 (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of arylpyridazinones as prostaglandin endoperoxide H synthase biosynthesis inhibitors)  
 RN 221026-47-7 CAPLUS  
 CN 3(2H)-pyridazinone, 2-(3-bromophenyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 OTHER SOURCE(S): MARPAT 130:223284  
 GI:




AB The title compds. [I; X = O, S, NR4, etc.; R4 = alkyl, alkenyl, cycloalkyl, etc.; R = H, alkyl, alkenyl, etc.; at least one of R1-R3 = I; II (wherein X1 = SO2, SO(NR10), SO, etc.; R9 = alkyl, alkenyl, alkenyl, etc.; X2 = H, halo, alkyl, etc.; R10 = H, alkyl, cycloalkyl); the remaining two of the groups of R1-R3 = H, OH, hydroxyalkyl, etc.] which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2), and therefore are useful in treating pain, fever, inflammation, rheumatoid arthritis, osteoarthritis, adhesions, and cancer, were prepared. Thus, oxidation of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (preparation given) with MeCO3H in CH2Cl2 afforded 86% I [X = O; R = PhCH2; R1 = 4-FC6H4; R2 = 4-(MeSO2)C6H4; R3 = H] which showed 0.014 μM against COX-2. COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal tract and the kidneys. The selectivity of the compds. I for COX 2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).  
 IT 221026-45-5P 221026-46-6P  
 RL: BAC (Biological activity or effector, except adverse); BSU  
 (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of arylpyridazinones as prostaglandin endoperoxide H synthase biosynthesis inhibitors)  
 RN 221026-45-5 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-(4-fluorophenoxy)-2-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 221026-48-8 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(3,5-difluorophenyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221026-49-9 CAPLUS  
 CN 3(2H)-Pyridazinone, 2-(3-chlorophenyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221028-72-4 CAPLUS  
 CN 3(2H)-Pyridazinone, 4-(4-chlorophenoxy)-2-(3,4-difluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 221028-73-5 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(4-(4-bromophenoxy)-2-(3,4-difluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221029-36-3 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(3-(3-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-4-phenoxy- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 221029-92-1 CAPLUS  
CN Benzenesulfonamide, 4-[5-(4-fluorophenoxy)-1-(3,4-difluorophenyl)-1,6-dihydro-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 221029-95-4 CAPLUS  
CN Benzenesulfonamide, 4-[1-(3,4-difluorophenyl)-5-(4-fluorophenoxy)-1,6-dihydro-6-oxo-4-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 221030-14-4 CAPLUS  
CN Benzenesulfonamide, 4-[1-(3,4-difluorophenyl)-5-(4-fluorophenoxy)-1,6-dihydro-6-oxo-4-pyridazinyl]-2-fluoro- (9CI) (CA INDEX NAME)

Habte


L4 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 221029-37-4 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(3-(3-chlorophenyl)-4-(3-(dimethylamino)phenoxy)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221029-39-6 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(3-(3-chlorophenyl)-4-(4-methoxyphenoxy)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221029-45-4 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(3-(3,4-difluorophenyl)-5-[3-fluoro-4-(methylsulfonyl)phenyl]-4-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 221030-18-8 CAPLUS  
CN 3(2H)-Pyridazinone, 2-(3-(3-chlorophenyl)-4-(3-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

07/30/2007

L4 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1995:995838 CAPLUS  
 DOCUMENT NUMBER: 124:117336  
 TITLE: Method of preparing p-substituted derivatives of  
 u-phenoxypropionic acid  
 INVENTOR(S): Popova, N. F.; Antipanova, N. S.; Valitov, R. B.;  
 Sharifyanova, L. N.; Sapozhnikov, Yu. E.; Emeleva, F.  
 S  
 PATENT ASSIGNEE(S): Vsesoyuznyi Nauchno-Issledovatel'skii  
 Tekhnologicheskii  
 SOURCE: Institut Gerbitsidov i Regulyatorov Rosta Rastanii,  
 USSR  
 U.S.S.R. From: Izobreteniya 1995, (9), 152-3.  
 CODEN: URXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Russian  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:  


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
SU 1681500	A1	19950327	SU 1989-4680340	19890418
PRIORITY APPLN. INFO.:			SU 1989-4680340	19890418

 OTHER SOURCE(S): CASREACT 124:117336  
 GI




AB Title derivs. 1 [R = Q1, Q2, Q3] are prepared more simply by reaction of  
 corresponding heterocyclic chloro compds. with 4-HOC6H4OCHMeCO2H under  
 heating in 1:(1-2) (weight/weight) dioxane/water mixture  
 IT 173061-79-5P  
 RL: IMP (Industrial manufacture); SPN (Synthetic preparation); PREP  
 (Preparation)  
 (preparation of p-(heterocycloxy)-substituted derivs. of  
 u-phenoxypropionic acid)  
 RN 173061-79-5 CAPLUS  
 CN Propenoic acid, 2-[4-[(2,3-dihydro-3-oxo-2-phenyl-4-  
 pyridazinyl)oxy]phenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1989:231558 CAPLUS  
 DOCUMENT NUMBER: 110:231558  
 TITLE: The reaction of 2-substituted-4,5-dichloro-3(2H)-  
 pyridazinones with alkoxides and alkylthiolates  
 AUTHOR(S): Lyga, John W.  
 CORPORATE SOURCE: Chem. Res. Dev. Cent., FMC Corp., Princeton, NJ,  
 08543, USA  
 SOURCE: Journal of Heterocyclic Chemistry (1988), 25(6),  
 1757-60  
 CODEN: JHTCAD; ISSN: 0022-152X  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 110:231558  
 GI




AB The reaction of 2-substituted-4,5-dichloro-3(2H)-pyridazinones I (R = Ph,  
 Me) with alkoxides and alkylthiolates was investigated. Regioselective  
 displacement of either the 4 or 5 Cl atom could be achieved in most cases  
 by appropriate selection of the reaction solvent.  
 IT 38387-54-1P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, by regioselective substitution of  
 dichloropyridazinone)  
 RN 38387-54-1 CAPLUS  
 CN 3(2H)-Pyridazinone, 5-chloro-4-phenoxy-2-phenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L4 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1986:207222 CAPLUS  
 DOCUMENT NUMBER: 104:207222  
 TITLE: Synthesis, spectral properties, and IHR of  
 2,4,5-trisubstituted 3-oxo-2H-pyridazines  
 AUTHOR(S): Konecny, V.; Kovac, S.; Varkonda, S.  
 CORPORATE SOURCE: Res. Inst. Chem. Technol., Bratislava, CS-831 06,  
 Czech.  
 SOURCE: Chemical Papers (1985), 39(4), 513-26  
 CODEN: CHPAEG; ISSN: 0366-6352  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 104:207222  
 AB The synthesis of 2-R2-4-alkoxy-5-chloro-, 2-R2-5-alkoxy-4-chloro-, and  
 2-R2-4,5-dialkoxy-3-oxo-2H-pyridazines by the reaction of  
 2-R2-4,5-dichloro- or 2-R2-4-chloro-5-alkoxy- or  
 2-R2-5-alkoxy-4-chloro-3-  
 oxo-2H-pyridazines with sodium alcoholate or alc. in the presence of  
 alkaline  
 carbonate in aprotic or protic solvent is described. IR and UV spectra  
 of  
 the prepared compds. are interpreted. Prepared compds. were tested for  
 fungicidal and herbicidal activity. In fungicidal activity none of the  
 prepared compds. reached the activity of the standard Vitavax; in the  
 inhibiting  
 the Hill reaction, 2-cyclohexyl-4-methoxy-5-chloro-2-(3'-methylphenyl)-4-  
 methoxy-5-chloro-, 2-(3'-chlorophenyl)-4-methoxy-5-chloro-,  
 2-cyclohexyl-4-chloro-5-methoxy-, 2-phenyl-4-chloro-5-methoxy-,  
 2-(3'-chlorophenyl)-4-chloro-5-methoxy-, 2-phenyl-4,5-dimethoxy-2-(3'-  
 trifluoromethylphenyl)-4,5-dimethoxy-3-oxo-2H-pyridazines reached or  
 surpassed the activity of the standard Pyrazon.  
 IT 7692-04-8P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and herbicidal and fungicidal activity of)  
 RN 7692-04-8 CAPLUS  
 CN 3(2H)-Pyridazinone, 4,5-diphenoxy-2-phenyl- (7CI, 8CI, 9CI) (CA INDEX  
 NAME)




L4 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1980:197448 CAPLUS  
 DOCUMENT NUMBER: 92:197448  
 TITLE: Spectral properties and intramolecular hydrogen bonding in 1-methyl(phenyl)-4(5)-substituted 6-oxo-1H-pyridazin-4(5)-ols  
 AUTHOR(S): Kovac, Stefan; Konecny, Vaclav  
 CORPORATE SOURCE: Dep. Org. Chem., Slovak Inst. Technol., Bratislava, 880 37, Czech.  
 SOURCE: Collection of Czechoslovak Chemical Communications (1980), 45(1), 127-34  
 CODEN: CCCCAK; ISSN: 0366-547X  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB IR, UV, 1H-NMR data of 53 title compds. were determined Intramol. H bonding was discussed. Relatively strong H bonding OH...S was found. Wave nos. of  $\nu$  (C=O) and  $\nu$  (O-H) bands linearly correlated with substituent constn.  $\sigma^+$ ,  $\sigma_R$  and  $\sigma_P$ . The UV spectra of these compds. were characterized by 2 bands: the bands at lower wavelengths belonged to  $\pi^* \leftarrow \pi$  transitions, whereas those at the longest wavelengths to  $\pi^* \leftarrow n$  transitions.  
 IT 36096-27-2  
 RL: PRP (Properties) (spectra of)  
 RN 36096-27-2 CAPLUS  
 CN 3(2H)-Pyridazinone, 5-hydroxy-6-phenoxy-2-phenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


L4 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1977:535236 CAPLUS  
 DOCUMENT NUMBER: 87:135236  
 TITLE: Preparation of 2,4-disubstituted 5-hydroxy-3(2H)-pyridazinones and 2,5-disubstituted 4-hydroxy-3(2H)-pyridazinones  
 AUTHOR(S): Konecny, V.  
 CORPORATE SOURCE: Res. Inst. Agrochem. Technol., Bratislava, Czech.  
 SOURCE: Chemicke Zvesti (1976), 30(5), 663-73  
 CODEN: CHZVAN; ISSN: 0366-6352  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 87:135236  
 GI




AB The synthesis of pyridazinones I (R = Cl, Br, alkoxy, alkylthio; R1 = H, Me, Et, Pr, Me2CH, allyl, Bu CH2CH2CClMe, octyl, etc.) and II (R = Cl, Br, alkoxy, alkylthio; R1 = Me, Ph, cyclohexyl) in 36.8-91.2% yield by alkaline hydrolysis of 2-substituted 4,5-dihalo-3(2H)-pyridazinones, 2-substituted 4,5-dialkoxy-3(2H)-pyridazinones, 2-substituted 4-alkoxy-5-halo-3(2H)-pyridazinones, 2-substituted 4-halo-5-alkoxy-3(2H)-pyridazinones, 2-substituted 4-halo(alkylthio)-5-alkylthio(halo)-3(2H)-pyridazinones or by reaction of NaI with 2-substituted-4,5-dialkoxy(alkylthio)-3(2H)-pyridazinones was described.  
 IT 36096-27-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)  
 RN 36096-27-2 CAPLUS  
 CN 3(2H)-Pyridazinone, 5-hydroxy-6-phenoxy-2-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1976:488449 CAPLUS  
 DOCUMENT NUMBER: 85:88449  
 TITLE: Synthesis, insecticidal and acaricidal properties of some 5-alkoxy-, 5-alkylthio-6-oxo-1-phenyl-1H-pyridazin-4-yl and 6-oxo-5-phenoxy-1-phenyl-1H-pyridazinyl phosphorus esters. II  
 AUTHOR(S): Konecny, Vaclav  
 CORPORATE SOURCE: Res. Inst. Agrochem. Technol., Bratislava, Czech.  
 SOURCE: Pesticide Science (1976), 7(2), 97-106  
 CODEN: PSSCBG; ISSN: 0031-613X  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI




AB Of 88 new 5-alkoxy-, 5-alkylthio-6-oxo-1-phenyl-1H-pyridazin-4-yl and 6-oxo-5-phenoxy-1-phenyl-1H-pyridazin-4-yl P esters, e.g., I [37840-60-1], a number showed strong pesticidal activities, although none showed strong aphicidal activity. The diethyl and dimethyl phosphates, and OO-diethyl and OO-dimethyl phosphorothioates showed especially high insecticidal and acaricidal activity.  
 IT 37840-69-OP 37840-70-3P 60245-47-8P  
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and insecticidal and acaricidal activity of)  
 RN 37840-69-0 CAPLUS  
 CN Phosphorothioic acid, O-(1,6-dihydro-6-oxo-5-phenoxy-1-phenyl-4-pyridazinyl) O-ethyl O-methyl ester (9CI) (CA INDEX NAME)




RN 37840-70-3 CAPLUS  
 CN Phosphoric acid, 1,6-dihydro-6-oxo-5-phenoxy-1-phenyl-4-pyridazinyl dimethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 60245-47-8 CAPLUS  
 CN Phosphonothioic acid, ethyl-, O-(1,6-dihydro-6-oxo-5-phenoxy-1-phenyl-4-pyridazinyl) O-ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L4 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 1974:116994 CAPLUS  
 DOCUMENT NUMBER: 80:116994  
 TITLE: Synthesis and biological properties of aryl and pyridazinyl sulfonates  
 AUTHOR(S): Konecny, V.; Demecko, J.  
 CORPORATE SOURCE: Res. Inst. Agrochem. Technol., Bratislava-Predmestie, Czech.  
 SOURCE: Chemické Zvesti (1973), 27(4), 497-511  
 CODEN: CHZVAN; ISSN: 0366-6352  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Esters of sulfonic acids prepared by the reaction of the appropriate alkane- and arenesulfonyl chloride with the Na or K salt of the corresponding phenol or 5-hydroxy-2H-pyridazin-3-one, as well as 2,6-dihalogeno-4-cyanophenyl esters prepared by treating phenol or sulfonyl chloride with an aqueous solution of alkaline hydroxide in a heterogeneous phase were tested for insecticidal, acaricidal, ovicidal, fungicidal, and herbicidal efficacies. 2,6-Dihalogeno-4-cyanophenyl esters (I) showed good herbicidal. Properties which were in some cases equal to those of Joxynil (1689-83-4) (standard), the most active compound from this group was 2,6-diodo-4-cyanophenyl chloromethanesulfonate (I, R = ClMe, X = I) [33840-65-2]. The herbicidal efficacy of 2,6-dihalogeno-3-alkyl-4-nitrophenyl esters was lower than that of the used standard (Joxynil), however the acaricidal efficiency of 2,6-dibromo-4-nitrophenyl phenylmethanesulfonate [50862-08-3] was only slightly less active than the standard. Acrex [973-21-7]. Biol., the most interesting group was 2-alkyl-4,6-dinitrophenyl esters (II) from which the 2-alkyl-4,6-dinitrophenyl alkane-sulfonates displayed good herbicidal efficiencies, and 2-sec-butyl-4,6-dinitrophenyl 2-chloroethanesulfonate (II, R = sec-Bu, R1 = 2-ClEt) [50862-05-0], the appropriate chloromethanesulfonate and 2,3-dichloropropanesulfonate were more efficient acaricides than the used standard (Acrex). 2-(1-Methylheptyl)-4,6-dinitrophenyl 2,4,5-trichlorobenzenesulfonate [35168-82-2] and the appropriate 2-chloroethanesulfonate were very efficient as antipowdery mildew fungicidal seed dressings as compared with the standard, methylenedithionide [6317-18-6].  
 IT 52105-40-5P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 52105-40-5 CAPLUS  
 CN Benzenemethanesulfonic acid, 1,6-dihydro-6-oxo-5-phenoxy-1-phenyl-4-pyridazinyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1974:3546 CAPLUS  
 DOCUMENT NUMBER: 80:3546  
 TITLE: 1-Alkyl-1,6-dihydro-3(2H)-pyridazinones  
 INVENTOR(S): Kropp, Rudolf; Reicheneder, Franz  
 PATENT ASSIGNEE(S): Badische Anilin- & Soda-Fabrik AG  
 SOURCE: Ger. Offen., 20 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2213010	A1	19730920	DE 1972-2213010	19720317
PRIORITY APPLN. INFO.:			DE 1972-2213010	A 19720317

GI For diagram(a), see printed CA Issue.  
 AB Twenty-nine pyridazinones I; R = e.g. OH, SPh, SCH<sub>2</sub>CH<sub>2</sub>NEt<sub>2</sub>, CN, CH(CN)<sub>2</sub>, Et, NHPh, or morpholino; R1 = H, Cl, Me, OMe, NH<sub>2</sub>, NEt<sub>2</sub>, or NHPh; R2 = H, Cl, Br, SEt, SPh, OMe, or OPh; R3 = Ph or Me; R4 = Me or Et; or RR4 = benzo] were prepared in 30.1-98.4% yield by reaction of the salts II (X = ClO<sub>4</sub> or MeSO<sub>4</sub>) with RY (Y = H, Na, K, or MgBr) at pH ≥ 6.5. Thus, Et<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>SH.HCl was added to I1 (R1 = NH<sub>2</sub>, R2 = Cl, R3 = Ph, R4 = Me, X = MeSO<sub>4</sub>) in H<sub>2</sub>O and pH 7.5-8 adjusted by NaOH at 20-5° to give 84.7% I (R = SCH<sub>2</sub>CH<sub>2</sub>NEt<sub>2</sub>, R1 = NH<sub>2</sub>, R2 = Cl, R3 = Ph, R4 = Me).  
 IT 50306-36-0  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (simultaneous dequaternization-addition reaction of, with nucleophiles)  
 RN 50306-36-0 CAPLUS  
 CN Pyridazinium, 5-chloro-1-ethyl-2,3-dihydro-3-oxo-4-phenoxy-2-phenyl-, tetrafluoroborate(1-) (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 50581-56-1  
 CMP C18 H16 Cl N2 O2




CM 2  
 CRN 14874-70-5  
 CMP B F4  
 CCI CCS


L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L4 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 CN 3(2H)-Pyridazinone, 5-chloro-4-(4-methoxyphenoxy)-2-phenyl- (9CI) (CA INDEX NAME)



RN 42190-49-8 CAPLUS  
 CN 3(2H)-Pyridazinone, 5-chloro-4-(4-chlorophenoxy)-2-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1973:453245 CAPLUS

DOCUMENT NUMBER: 79:53245

TITLE: Mucochloric acid utilization in the synthesis of fungicides

AUTHOR(S): Krawczynska, Bogumila; Eckstein, Zygmunt  
 CORPORATE SOURCE: Inst. Chem. Technol. Org., Politechnika Warszawska, Warsaw, Pol.

SOURCE: Przemysl Chemiczny (1973), 52(4), 276-9

CODEN: PRCHAB; ISSN: 0033-2496

DOCUMENT TYPE: Journal

LANGUAGE: Polish

GI For diagram(s), see printed CA Issue.

AB cis-OHCCl:CClCO2R (R = H, Me) condensed under alkaline conditions with ArOH

[Ar = Ph, 4-MeOC6H4, 3,4-Me(Cl)C6H3, 4-BrC6H4, 4-ClC6H4, 2-MeC6H4, 4-MeC6H4, 2,4,5-Cl3C6H2] to yield I (X = ArO, Y = Cl; X = Cl, Y = ArO) in equilibrium with OHCCY:CClCO2R. I reacted with MeNO2 to give I (OR = CH2NO2)

and with PhNHNH2 to give II.

IT 7692-04-8P 38387-54-1P 42190-48-7P


42190-49-8P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)


RN 7692-04-8 CAPLUS

CN 3(2H)-Pyridazinone, 4,5-diphenoxy-2-phenyl- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 38387-54-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-chloro-4-phenoxy-2-phenyl- (9CI) (CA INDEX NAME)



RN 42190-48-7 CAPLUS

L4 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1972:539948 CAPLUS

DOCUMENT NUMBER: 77:139948

TITLE: Synthesis of 4-halo-5-phenoxy-6-pyridazines based on halomucic acids

AUTHOR(S): Karklina, A.; Gudriniece, E.; Paulina, J.

CORPORATE SOURCE: Rzh. Politekh. Inst., Riga, USSR

SOURCE: Latvijas PSR Zinatnu Akademijas Vestis, Kimijas Serija

(1972), (4), 496-7

CODEN: LZAKAM; ISSN: 0002-3248

DOCUMENT TYPE: Journal

LANGUAGE: Russian

GI For diagram(s), see printed CA Issue.

AB 5-Halo-4-phenoxy-3(2H)pyridazinones [I, R = H, Me, CH2CH2OH, Ph; X = Cl, Br] were prepared in 51-88% yields by treating OHCCX:CClCO2H (X = Br, Cl) with PhOH and KOH to give OHCCX:Cl(OPh)CO2H, which were subsequently cyclized with RNHNH2 to give the title compds. I.


IT 38387-54-1P 38387-58-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)


RN 38387-54-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-chloro-4-phenoxy-2-phenyl- (9CI) (CA INDEX NAME)



RN 38387-58-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-bromo-4-phenoxy-2-phenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1972:462016 CAPLUS  
 DOCUMENT NUMBER: 77:62016  
 TITLE: Insecticidal and acaricidal pyridazinonyl-4 organophosphates  
 INVENTOR(S): Konecny, Vaclav; Sirota, Teobald  
 SOURCE: Czech., 14 pp.  
 CODEN: CZXXA9  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Czech  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CS 141951		19710715	CS 1969-2934	19690425

GI For diagram(s), see printed CA Issue.  
 AB 1(X = O or S) are prepared by reaction of R1R2PXCl with the corresponding substituted alkali 6-pyridazinone-4-hydroxylates. Thus, 17.9 g X salt of 1-phenyl-4-hydroxy-5-methoxy-6-pyridazinone was treated in 100 ml MeCN with 13.1 g iso-Pr-(MeO)PSCl and the mixture refluxed 7 hr to give 26 g O-methyl O-(1-phenyl-5-methoxy-6-pyridazinon-4-yl) N-isopropylamidothiophosphate. Similarly prepared were 39 addnl. I. I were tested against Musca domestica (housefly), Calandra granaria (Sitophilus granarius), Tetranychus urticae (Tetranychus telarius), Aphis fabae, and Macrosiphoniella sanborni and found applicable in solution, aqueous emulsion, suspension, powder, and granulate.  
 IT 37840-68-9P 37840-69-0P 37840-70-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 37840-68-9 CAPLUS  
 CN Phosphorothioic acid, ethyl-, O-(1,6-dihydro-6-oxo-5-phenoxy-1-phenyl-4-pyridazinyl) O-methyl ester (9CI) (CA INDEX NAME)




RN 37840-69-0 CAPLUS  
 CN Phosphorothioic acid, O-(1,6-dihydro-6-oxo-5-phenoxy-1-phenyl-4-pyridazinyl) O-ethyl O-methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 37840-70-3 CAPLUS  
 CN Phosphoric acid, 1,6-dihydro-6-oxo-5-phenoxy-1-phenyl-4-pyridazinyl dimethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1972:140853 CAPLUS  
 DOCUMENT NUMBER: 76:140853  
 TITLE: 4-Hydroxy-6-pyridazones  
 INVENTOR(S): Konecny, Vaclav  
 SOURCE: Czech., 5 pp.  
 CODEN: CZXXA9  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Czech  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CS 140062		19710215	CS 1969-3314	19690512

GI For diagram(s), see printed CA Issue.  
 AB The pyridazones (I, R = alkyl, aryl, X = O, S) were prepared by treating with NaOH or KOH. Thus, II (R = Et, X = O, R1 = Ph), was treated with NaOH and the product neutralized with HCl to give I (R = Et, X = O, R1 = Ph). Similarly prepared were 8 I.  
 IT 36096-27-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 36096-27-2 CAPLUS  
 CN 3(2H)-Pyridazinone, 5-hydroxy-6-phenoxy-2-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1966:473553 CAPLUS  
 DOCUMENT NUMBER: 65:73553  
 ORIGINAL REFERENCE NO.: 65:13731c-g  
 TITLE: Pyridazones  
 INVENTOR(S): Reicheneder, Franz; Dury, Karl  
 PATENT ASSIGNEE(S): Badische Anilin- & Soda-Fabrik A.-G.  
 SOURCE: 18 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Unavailable  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 665583		19651217	BE	19650617

PRIORITY APPLN. INFO.: DE 19640619

GI For diagram(s), see printed CA Issue.  
 AB The new compds., I, were obtained by the reaction of a pyridazone II with an alc. or a phenol R4OH at 90-150° in the presence of at least the stoichiometric amount of a basic compound, e.g. an alcoholate, phenolate, hydroxide, or carbonate. The starting materials were obtained by the reaction of γ-hydroxycrotonic acid or its lactone substituted by Cl and (or) Br in α- and β-position with hydrazine or hydrazide, (Bruckner and Kardoos, CA 29, 58256). Thus, 241 parts 1-phenyl-4,5-dichloro-6-pyridazone was suspended in 1300 parts PhMe. Traces of H2O were separated by azeotropic distillation with PhMe. A solution (350 parts) of 30% MeONa in MeOH was added in portions, a mixture of MeOH and PhMe distilled until the temperature of the residual solution rose to 110°. The solution was stirred 1 hr. at 110°, cooled, and acidified with dilute HCl, and the precipitate dried in vacuo to give 210 parts 1-phenyl-4,5-dimethoxy-6-pyridazone, m. 143-4° (MeOH). Similarly prepared were the following I: R1, R2, R3, R4, m.p.; Ph, H, Et, Et, 79-80° (cyclohexane); Ph, H, benzyl, benzyl, 90-1° (MeOH); Ph, H, β-phenoxy-ethyl, β-phenoxyethyl, 91-3° (cyclohexane); Me, H, β-phenoxyethyl, β-phenoxyethyl, 74-6° (MeOH); Ph, H, β-anilinoethyl, β-anilinoethyl, 134° (toluene); Ph, H, β-dimethylaminoethyl, β-dimethylaminoethyl, 185-6° (H2O-MeOH); p-tolyl, H, Me, Me, 95-6° (cyclohexane); Ph, H, Ph, Ph, 129-11° (MeOH); H, H, Ph, Ph, 175-6° (MeOH); benzyl, benzyloxy, Me, Me, 75-6° (cyclohexane); benzyl, benzyloxy, H, Me, 150-150.5 (CH3CN); Me, Ph, Me, Me, 106-7° (MeOH); Me, H, Me, Me, 60-1° (cyclohexane); cyclohexyl, H, Me, Me, 60-1° p-chlorophenyl, H, Me, Me, 139-40° (MeOH); 3,4-dichlorophenyl, H, Me, Me, 159-60° (MeOH); Ph, H, p-cresyl, p-cresyl, 86-8° (MeOH). The new pyridazones are herbicides and stabilizers for plastics.  
 IT 7692-04-8P, 3(2H)-Pyridazinone, 4,5-diphenoxy-2-phenyl  
 7692 13-9P, 3(2H)-Pyridazinone, 2-phenyl 4,5-bis(p-tolyloxy)-  
 RL: PREP (Preparation)  
 (preparation of)  
 RN 7692-04-8 CAPLUS  
 CN 3(2H)-Pyridazinone, 4,5-diphenoxy-2-phenyl- (7CI, 8CI, 9CI) (CA INDEX NAME)



L4 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 7692-13-9 CAPLUS  
CN 3(2H)-Pyridazinone, 2-phenyl-4,5-bis(p-tolyloxy)- (7CI, 8CI) (CA INDEX NAME)

